BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Breast Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Breast Cancer\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02605486-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT02605486)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Palbociclib in Combination With Bicalutamide for the Trea
 tment of AR(+) Metastatic Breast Cancer (MBC)\nEstimated primary completio
 n: November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pal
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT02605486
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06048718-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06048718)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd Therapy for HER2-low Breast Cancer Patients With Bra
 in Metastases\nEstimated primary completion: November 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06048718
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05323955-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05323955)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Secondary BRain M
 etastases Prevention After Isolated Intracranial Progression on Trastuzuma
 b/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Fac
 tor Receptor 2+ brEast Cancer With the Addition of Tucatinib\nEstimated pr
 imary completion: November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05323955
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05323955-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT05323955)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Second
 ary BRain Metastases Prevention After Isolated Intracranial Progression on
  Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal
  Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib\nE
 stimated primary completion: November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05323955
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05323955-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05323955)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Secondary BRain Me
 tastases Prevention After Isolated Intracranial Progression on Trastuzumab
 /Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Fact
 or Receptor 2+ brEast Cancer With the Addition of Tucatinib\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05323955
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05596409-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elacestrant: Phase 2 readout est. (NCT05596409)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Rec
 eptor Positive\, HER-2 Negative Metastatic Breast Cancer Study\nEstimated 
 primary completion: November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05596409
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05607004-9122@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:(Z)-endoxifen: Phase 2 readout est. (NCT05607004)
DESCRIPTION:(Z)-endoxifen\, phase 2\, Breast Cancer.\nStudy: (Z)-Endoxifen 
 for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer\nEst
 imated primary completion: November 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/z-endoxifen#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05607004
URL:https://assetmemo.bio/drug/z-endoxifen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107686-1982@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06107686)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Selected Patients With Advanced Solid Tumors\nE
 stimated primary completion: November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06107686
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954961-9088@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taragarestrant: Phase 3 readout est. (NCT06954961)
DESCRIPTION:Taragarestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Adva
 nced or Metastatic Breast Cancer\nEstimated primary completion: 30 Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/taragarestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 954961
URL:https://assetmemo.bio/drug/taragarestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05546268-2661@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MRT-2359: Phase 1/2 readout est. (NCT05546268)
DESCRIPTION:MRT-2359\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Oral MRT-2359 in Selected Cancer Patients\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mr
 t-2359#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05546268
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115306-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT04115306)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase 1/1b/2 Study of Oral PMD-026 in Patients With Meta
 static Breast Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04115306
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202261-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of TQB2930 for Injection Monotherapy or Combinat
 ion Therapy in Patients With Recurrent/Metastatic Breast Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06202261
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974929-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens i
 n Patients With Breast Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202261-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study of TQB2930 for Injection Monotherapy or Combination Therap
 y in Patients With Recurrent/Metastatic Breast Cancer\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06202261
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202261-9077@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Culmerciclib: Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Culmerciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study of TQB2930 for Injection Monotherapy or Combination Therap
 y in Patients With Recurrent/Metastatic Breast Cancer\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06202261
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455619-9078@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Evexomostat: Phase 1/2 readout est. (NCT05455619)
DESCRIPTION:Evexomostat\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients 
 With a PI3K Alteration and HR+/Her2- Breast Cancer\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/evexomostat#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05455619
URL:https://assetmemo.bio/drug/evexomostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974929-9146@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-6209: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:SHR-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in
  Patients With Breast Cancer\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/shr-6209#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974929-9181@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-6209: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:HRS-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in
  Patients With Breast Cancer\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/hrs-6209#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974929-11083@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-2189: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:HRS-2189\, phase 1/2\, Breast Cancer.\nStudy: A Clinical Study 
 of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast
  Cancer\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hrs-2189#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/hrs-2189#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02644369-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02644369)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of the 
 Effects of Pembrolizumab in Patients With Advanced Solid Tumors\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT02644369
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645380-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05645380)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant TI
 L- and Response-Adapted Chemoimmunotherapy for TNBC\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05645380
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03125928-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT03125928)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Cli
 nical Trial of Atezolizumab With Paclitaxel\, Trastuzumab\, and Pertuzumab
  in Patients With Metastatic HER-2 Positive Breast Cancer\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03125928
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02738866-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT02738866)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Palbociclib With Fulvestrant for Metastatic Breast Cancer 
 After Treatment With Palbociclib and an Aromatase Inhibitor\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT02738866
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02738866-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02738866)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Palbociclib With Fulvestrant for Metastatic Breast Cancer A
 fter Treatment With Palbociclib and an Aromatase Inhibitor\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT02738866
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538896-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06538896)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Tislelizumab 
 Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-N
 egative Breast Cancer with Bone Metastasis，an Exploratory\, Single-Arm\,
  Multicenter Phase II Clinical Study\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6538896
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03740893-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 2 readout est. (NCT03740893)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: PHOENIX DDR/Anti-PD
 -L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant
  Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD
 -L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residua
 l Triple Negative Breast Cancer\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03740893
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06042894-2044@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06042894)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With U
 nresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast 
 Cancer\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06042894
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891561-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05891561)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Sho
 rt-course Trastuzumab\, Pertuzumab with Taxanes in the Adjuvant Treatment 
 of Early HER2-positive Breast Cancer\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05891
 561
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800275-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05800275)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Capecitabine\, Tuc
 atinib\, and Intrathecal Trastuzumab for Breast Cancer Patients With Lepto
 meningeal Disease\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05800275
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05982093-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT05982093)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant With/Without Triptorelin in Premenopausal Women With Lumi
 nal Breast Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05982093
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800275-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05800275)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capecitabine\, Tucatinib\, and Intrathecal Trastuzumab for Breast Ca
 ncer Patients With Leptomeningeal Disease\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecit
 abine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05800275
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04639986-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04639986)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2
 - Metastatic Breast Cancer (MBC)\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04639986
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05780567)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Clinica
 l Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Com
 pared With Placebo Combined With Endocrine Therapy in Patients With Breast
  Cancer\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03820830-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT03820830)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Palbociclib for HR Positive / HER2-negative Isolated Locore
 gional Recurrence of Breast Cancer\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT038208
 30
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255612-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07255612)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: Bone Marro
 w Protection\, Safety\, Efficacy of Trilaciclib and Eribulin in Locally Ad
 vanced or Metastatic TNBC(Triple-negative Breast Cancer)\nEstimated primar
 y completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07255612
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05491226-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05491226)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Reinvigorating
  TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Ra
 diation\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05491226
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05305924-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05305924)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-P
 ositive\, Her2-Negative Metastatic Breast Cancer\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05305924
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05305924-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05305924)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-P
 ositive\, Her2-Negative Metastatic Breast Cancer\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05305924
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04290793-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Epirubicin: Phase 2/3 readout est. (NCT04290793)
DESCRIPTION:Epirubicin\, phase 2/3\, Breast Cancer.\nStudy: Neoadjuvant Che
 motherapy With Pyrotinib\, Epirubicin and Cyclophosphamide Followed by Tax
 anes and Trastuzumab for HER-2+ Breast Cancer\nEstimated primary completio
 n: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pirubicin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04290793
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05860465-9055@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SPH4336: Phase 2/3 readout est. (NCT05860465)
DESCRIPTION:SPH4336\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in
  the Treatment of Locally Advanced or Metastatic Breast Cancer\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sph4336#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05860465
URL:https://assetmemo.bio/drug/sph4336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446452-2454@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07446452)
DESCRIPTION:Disitamab Vedotin\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breas
 t Cancer After T-DXd Failure: A Phase II Study\nEstimated primary completi
 on: 6 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07446452
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-2704@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:rezatapopt: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:rezatapopt\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a
  TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezatapopt#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0458575
 0
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245797-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07245797)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: A Phase II\, 
 Multicenter\, Open-label Study to Evaluate the Efficacy and Safety of Neoa
 djuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcuta
 neous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated\, HER
 2+\, eBC\nEstimated primary completion: 15 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07245797
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245797-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07245797)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: A Phase II\, Mult
 icenter\, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuv
 ant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneou
 s (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated\, HER2+\,
  eBC\nEstimated primary completion: 15 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07245797
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245797-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07245797)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Phase
  II\, Multicenter\, Open-label Study to Evaluate the Efficacy and Safety o
 f Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as S
 ubcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated
 \, HER2+\, eBC\nEstimated primary completion: 15 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07245797
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03595592-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT03595592)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Neoadjuvant Treat
 ment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer\n
 Estimated primary completion: 15 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03595592
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747338-2506@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT06747338)
DESCRIPTION:Docetaxel (HB1801)\, phase 3\, HER2-Positive Breast Cancer.\nSt
 udy: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin 
 as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breas
 t Cancer\nEstimated primary completion: 16 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06747338
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04886531-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Neratinib: Phase 2 readout est. (NCT04886531)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tria
 l of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-
 Positive\, HER-2 Positive Breast Cancers\nEstimated primary completion: 22
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nerat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04886531
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04886531-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Anastrozole: Phase 2 readout est. (NCT04886531)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzum
 ab in ER-Positive\, HER-2 Positive Breast Cancers\nEstimated primary compl
 etion: 22 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/anastrozole#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04886531
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04886531-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Letrozole: Phase 2 readout est. (NCT04886531)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab
  in ER-Positive\, HER-2 Positive Breast Cancers\nEstimated primary complet
 ion: 22 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04886531
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficac
 y Of Elacestrant In Various Combination In Participants With Metastatic Br
 east Cancer\nEstimated primary completion: 27 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacest
 rant In Various Combination In Participants With Metastatic Breast Cancer\
 nEstimated primary completion: 27 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Alpelisib (BYL719): Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Alpelisib (BYL719)\, phase 1/2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of
  Elacestrant In Various Combination In Participants With Metastatic Breast
  Cancer\nEstimated primary completion: 27 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Capivasertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elace
 strant In Various Combination In Participants With Metastatic Breast Cance
 r\nEstimated primary completion: 27 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacest
 rant In Various Combination In Participants With Metastatic Breast Cancer\
 nEstimated primary completion: 27 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy
  Of Elacestrant In Various Combination In Participants With Metastatic Bre
 ast Cancer\nEstimated primary completion: 27 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elaces
 trant In Various Combination In Participants With Metastatic Breast Cancer
 \nEstimated primary completion: 27 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05227664-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05227664)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: A Study of AK
 117/AK112 in Metastatic Triple-Negative Breast Cancer\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05227664
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03573648-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT03573648)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Endocrine Therapy\, Palbociclib\, Avelumab in Estrogen Receptor Posi
 tive Breast Cancer\nEstimated primary completion: 30 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03573648
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459738-2039@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43: Phase 2 readout est. (NCT07459738)
DESCRIPTION:HLX43\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy: A
  Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients W
 ith Hormone Receptor Positive\, HER2 Negative Locally Advanced or Metastat
 ic Breast Cancer\nEstimated primary completion: 30 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07459738
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03606967-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT03606967)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Testing the A
 ddition of an Individualized Vaccine to Durvalumab and Tremelimumab and Ch
 emotherapy in Patients With Metastatic Triple Negative Breast Cancer\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03606967
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03606967-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03606967)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Testin
 g the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab
  and Chemotherapy in Patients With Metastatic Triple Negative Breast Cance
 r\nEstimated primary completion: 30 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03606967
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04434040-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04434040)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Atezol
 izumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04434040
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05398861-2272@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Utidelone: Phase 2 readout est. (NCT05398861)
DESCRIPTION:Utidelone\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of 
 HER-2 Negative Advanced Breast Cancer\nEstimated primary completion: 30 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 398861
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letroz
 ole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9103@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Veppanu (Vepdegestrant): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letr
 ozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/vepdegestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03594396-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT03594396)
DESCRIPTION:Olaparib\, phase 1/2\, Breast Cancer.\nStudy: Window of Opportu
 nity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or L
 ow ER+ Breast Cancer\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03594396
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-9029@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combinat
 ion of Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04140526
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05491083-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05491083)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Pembrolizumab
  and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05491083
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286437-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05286437)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast
  Cancer With Letrozole\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05286437
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05675579-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05675579)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: A Phase II Stu
 dy of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immu
 nochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05675579
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05675579-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05675579)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: A Phas
 e II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy 
 for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer
  (TNBC)\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05675579
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00877500-2144@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ixabepilone: Phase 2 readout est. (NCT00877500)
DESCRIPTION:Ixabepilone\, phase 2\, Breast Cancer.\nStudy: Ixabepilone in T
 reating Participants With Significant Residual Disease of HER2/Neu Negativ
 e Invasive Breast Cancer After Systemic Therapy\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ixabepilone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT00877500
URL:https://assetmemo.bio/drug/ixabepilone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04553133)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: PF-07104091 as a Single Agent and in Combination Therapy\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04553133
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 2 readout est. (NCT04553133)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: PF-07104091 as a Single Agent and in Combination Therapy\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04553133
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286437-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 2 readout est. (NCT05286437)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Can
 cer With Letrozole\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05286437
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-11278@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tegtociclib: Phase 2 readout est. (NCT04553133)
DESCRIPTION:Tegtociclib\, phase 2\, Breast Cancer.\nStudy: PF-07104091 as a
  Single Agent and in Combination Therapy\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tegto
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04553133
URL:https://assetmemo.bio/drug/tegtociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359404-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07359404)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Sacitu
 zumab Govitecan Plus Bevacizumab in Metastatic TNBC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07359404
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06556862-2286@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06556862)
DESCRIPTION:Chidamide\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Canc
 er After Failure of CDK4/6 Inhibitor\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 56862
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06556862-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06556862)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Ca
 ncer After Failure of CDK4/6 Inhibitor\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dalpici
 clib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06556862
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06802757-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06802757)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Posaconazole 
 Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy 
 in Neoadjuvant Therapy for Triple Negative Breast Cancer\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06802757
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03804944-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03804944)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Converting HR+ Breast Cancer Into an Individualized Vaccine\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03804944
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635342-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07635342)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Pyro
 tinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Can
 cer\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07635342
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329065-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04329065)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Concurrent WOKVAC
  Vaccination\, Chemotherapy\, and HER2-Targeted Monoclonal Antibody Therap
 y Before Surgery for the Treatment of Patients With Breast Cancer\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04329065
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978648-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05978648)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trilaciclib in Pa
 tients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemo
 therapy\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05978648
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016387-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06016387)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tuca
 tinib\, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy
  (XRT) in Patients With HER2+\, HER2 Mutated and/or HER2-amplified Metasta
 tic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II\, Si
 ngle Arm Feasibility Study\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06016387
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05872347-9055@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SPH4336: Phase 2 readout est. (NCT05872347)
DESCRIPTION:SPH4336\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in B
 reast Cancer Patients With Brain Metastases.\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 ph4336#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05872347
URL:https://assetmemo.bio/drug/sph4336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076682-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05076682)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Revers
 e Triple Negative Immune Resistant Breast Cancer\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05076682
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978648-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05978648)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Trilaciclib in Pa
 tients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemo
 therapy\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05978648
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05424835-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT05424835)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Tria
 l of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Po
 sitive\, Unresectable and/or Metastatic Breast Cancer Subjects Previously 
 Treated With Trastuzumab and Taxane\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05424835
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081959-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06081959)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of SKB264 for Locally Advanced\, Recurrent or Metas
 tatic HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06081959
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561362-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04561362)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignanci
 es\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04561362
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04039230-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT04039230)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study to Evaluate Sacituzumab Govitecan in Combination Wi
 th Talazoparib in Patients With Metastatic Breast Cancer.\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04039230
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04039230-2243@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT04039230)
DESCRIPTION:Talazoparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study to Evaluate Sacituzumab Govitecan in Combination With Talazop
 arib in Patients With Metastatic Breast Cancer.\nEstimated primary complet
 ion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ta
 lazoparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04039230
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827613-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06827613)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Invikafusp Alfa (STAR0602)\, a Selective T Cel
 l Receptor (TCR)-Targeting\, Bifunctional Antibody-fusion Molecule\, in Co
 mbination With Sacituzumab Govitecan in Participants With Advanced Solid T
 umors\nEstimated primary completion: January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06827613
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827613-2742@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Invikafusp alfa: Phase 1/2 readout est. (NCT06827613)
DESCRIPTION:Invikafusp alfa\, phase 1/2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of Invikafusp Alfa (STAR0602)\, a Selective T Cell Rece
 ptor (TCR)-Targeting\, Bifunctional Antibody-fusion Molecule\, in Combinat
 ion With Sacituzumab Govitecan in Participants With Advanced Solid Tumors\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/invikafusp-alfa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06827613
URL:https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683679-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04683679)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Oth
 er Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor 
 Positive/Her2 Negative Breast Cancer\nEstimated primary completion: Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046
 83679
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683679-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Olaparib: Phase 2 readout est. (NCT04683679)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Ra
 diosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Posit
 ive/Her2 Negative Breast Cancer\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04683679
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486883-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06486883)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First
 -line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer 
 Patients Classified as Non-luminal Subtype\nEstimated primary completion: 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06486883
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05306041-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT05306041)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: Neoadju
 vant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+\, HR+\, 
 PIK3CA Mutant Early Breast Cancer\nEstimated primary completion: January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05306041
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06195306-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06195306)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Low Dos
 e Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Red
 uction\nEstimated primary completion: 1 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06195306
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673029-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:Trastuzumab Emtansine: Phase 3 readout est. (NCT07673029)
DESCRIPTION:Trastuzumab Emtansine\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive 
 Unresectable or Metastatic Breast Cancer\nEstimated primary completion: 9 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-emtansine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07673029
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06481956-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06481956)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: T-DM1 Combined Wi
 th CDK4/6 Inhibitor Ribociclib\nEstimated primary completion: 10 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06481956
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207734-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06207734)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Discontinuation of CDK4/6 Inhibitors in Patients With Meta
 static HR Positive\, HER2 Negative Breast Cancer\nEstimated primary comple
 tion: 10 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06207734
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207734-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06207734)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Discontinuation of CDK4/6 Inhibitors in Patients With Metas
 tatic HR Positive\, HER2 Negative Breast Cancer\nEstimated primary complet
 ion: 10 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06207734
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462092-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06462092)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Sacituzumab Govitecan and Intrathecal Chemotherapy for Tr
 eating Leptomeningeal Metastases From Her2-negative Breast Cancer\nEstimat
 ed primary completion: 15 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06462092
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462079-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06462079)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sacituzumab Govitecan Combined With Head Radiotherapy for H
 er2-negative Breast Cancer Brain Metastases\nEstimated primary completion:
  15 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sac
 ituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06462079
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797622-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06797622)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd T
 reatment for Brain Metastasis of HER2 Positive Breast Cancer\nEstimated pr
 imary completion: 15 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06797622
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764940-2272@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Utidelone: Phase 2 readout est. (NCT06764940)
DESCRIPTION:Utidelone\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitab
 ine in HER2-negative Breast Cancer Patients With Brain Metastases\nEstimat
 ed primary completion: 15 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06764940
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764940-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06764940)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capeci
 tabine in HER2-negative Breast Cancer Patients With Brain Metastases\nEsti
 mated primary completion: 15 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06764940
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05038735-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT05038735)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulv
 estrant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced 
 Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inh
 ibitor.\nEstimated primary completion: 28 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05038735
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04544189-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04544189)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study Assessing the Efficacy and Safety of Treatment With Alpe
 lisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and 
 Postmenopausal Women With Advanced Breast Cancer\nEstimated primary comple
 tion: 29 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alpelisib-byl719#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04544189
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159451-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07159451)
DESCRIPTION:Elacestrant\, phase 2\, Breast Cancer.\nStudy: A Short-term Pre
 operative\, Evaluating Activity and Safety of Elacestrant Monotherapy as C
 ompared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Pr
 emenopausal Patients With Stage I-II ER+/HER2- Breast Cancer\nEstimated pr
 imary completion: 29 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07159451
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134153-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07134153)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Exp
 ressing Breast Cancer With Leptomeningeal/Brain Metastases\nEstimated prim
 ary completion: 30 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07134153
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT04906395)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Aceta
 te in Breast Cancer\nEstimated primary completion: 30 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Anastrozole: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Bre
 ast Cancer\nEstimated primary completion: 30 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Letrozole: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breas
 t Cancer\nEstimated primary completion: 30 January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Exemestane: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Brea
 st Cancer\nEstimated primary completion: 30 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03971409-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03971409)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Avelum
 ab With Binimetinib\, Sacituzumab Govitecan\, or Liposomal Doxorubicin in 
 Treating Stage IV or Unresectable\, Recurrent Triple Negative Breast Cance
 r\nEstimated primary completion: 31 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03971409
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT02476786)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Endocri
 ne Treatment Alone for Elderly Patients With Estrogen Receptor Positive Op
 erable Breast Cancer and Low Recurrence Score\nEstimated primary completio
 n: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 amoxifen-soltamox#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT02476786
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364267-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06364267)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal
  Women at High Risk for Breast Cancer.\nEstimated primary completion: 31 J
 anuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxife
 n-soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06364267
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT02476786)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Endoc
 rine Treatment Alone for Elderly Patients With Estrogen Receptor Positive 
 Operable Breast Cancer and Low Recurrence Score\nEstimated primary complet
 ion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02476786
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Exemestane: Phase 2 readout est. (NCT02476786)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: Endocrine Treatme
 nt Alone for Elderly Patients With Estrogen Receptor Positive Operable Bre
 ast Cancer and Low Recurrence Score\nEstimated primary completion: 31 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0247
 6786
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364267-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Exemestane: Phase 2 readout est. (NCT06364267)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at 
 High Risk for Breast Cancer.\nEstimated primary completion: 31 January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06364267
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612203-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06612203)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Clinical Study to Evaluate Debio0123 + Sacituzumab Govite
 can Combination in TNBC or HR+/HER2- Advanced Breast Cancer\nEstimated pri
 mary completion: February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06612203
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612203-9091@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zedoresertib: Phase 1/2 readout est. (NCT06612203)
DESCRIPTION:Zedoresertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combi
 nation in TNBC or HR+/HER2- Advanced Breast Cancer\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zedoresertib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06612203
URL:https://assetmemo.bio/drug/zedoresertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238921-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06238921)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: Saci
 tuzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic T
 riple Negative Breast Cancer With Brain Metastases\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06238921
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708194-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT07708194)
DESCRIPTION:Pyrotinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: En
 tinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive 
 Breast Cancer After Trastuzumab Failure\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 08194
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325632-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05325632)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Stu
 dy of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel\, Tra
 stuzumab & Pertuzumab\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05325632
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Sacit
 uzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Ch
 oice and Pembrolizumab in Patients With Previously Untreated\, Locally Adv
 anced Inoperable or Metastatic Triple-Negative Breast Cancer\nEstimated pr
 imary completion: February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice and Pembrolizumab in Patients With Previously Untreated\, Loc
 ally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06447623-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06447623)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Apatinib Combined With cdk4/6i in First-line Treatment for
  HR+/HER2- SNF4 Subtype Breast Cancer\nEstimated primary completion: 1 Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6447623
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271837-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06271837)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of T-DXd as Monotherapy or in Combination With Ant
 i-cancer Agents in Patients With Selected HER2-expressing Tumors\nEstimate
 d primary completion: 10 February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06271837
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492759-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06492759)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: High Dose Rad
 iation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Pa
 tients With PD-L1 Positive Metastatic Triple Negative Breast Cancer\nEstim
 ated primary completion: 12 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06492759
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492759-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06492759)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: High Dose Radi
 ation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Pat
 ients With PD-L1 Positive Metastatic Triple Negative Breast Cancer\nEstima
 ted primary completion: 12 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06492759
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341621-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06341621)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Chemo
 therapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes 
 Receiving Extended Adjuvant Abemaciclib\nEstimated primary completion: 25 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemac
 iclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06341621
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breast Cancer
 \nEstimated primary completion: 26 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Alpelisib (BYL719)\, phase 1/2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breas
 t Cancer\nEstimated primary completion: 26 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breast Cancer\
 nEstimated primary completion: 26 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Learn About the Study Medicine (Called PF-07220060 in Comb
 ination With PF-07104091) In Participants With Breast Cancer and Solid Tum
 ors\nEstimated primary completion: 26 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-9131@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Atirmociclib: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Atirmociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Learn About the Study Medicine (Called PF-07220060 in C
 ombination With PF-07104091) In Participants With Breast Cancer and Solid 
 Tumors\nEstimated primary completion: 26 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-11278@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Tegtociclib: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Tegtociclib\, phase 1/2\, Breast Cancer.\nStudy: A Study to Lea
 rn About the Study Medicine (Called PF-07220060 in Combination With PF-071
 04091) In Participants With Breast Cancer and Solid Tumors\nEstimated prim
 ary completion: 26 February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tegtociclib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/tegtociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524000-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04524000)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study Assessing the Efficacy and Safety of Treatment With Alpe
 lisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advan
 ced Breast Cancer\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04524000
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524000-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04524000)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study Assessing the Efficacy and Safety of Treatment With 
 Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With A
 dvanced Breast Cancer\nEstimated primary completion: 26 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04524000
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208178-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT04208178)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, Breast Cancer.\nStudy: Study of 
 Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maint
 enance Therapy in Patients With HER2-positive Advanced Breast Cancer With 
 a PIK3CA Mutation\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04208178
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04733118-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04733118)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Chemotherapy-Free
  pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positiv
 e Early Breast Cancer\nEstimated primary completion: March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04733118
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04733118-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04733118)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Chemot
 herapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in H
 ER2-positive Early Breast Cancer\nEstimated primary completion: March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4733118
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07305246-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07305246)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Clinic
 al Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for
  Early-Stage HR-Positive\, HER2-Low Breast Cancer\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tr
 astuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07305246
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416253-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07416253)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant
  Treatment of HER2 Positive Breast Cancer\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07416253
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433609-2064@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06433609)
DESCRIPTION:Notiretatug rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of ADCs Combined With Adebrelimab in HER2-negative Ad
 vanced Breast Cancer\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06433609
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433609-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06433609)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of ADCs Combined With Adebrelimab in HER2-negative Ad
 vanced Breast Cancer\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06433609
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771871-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epirubicin: Phase 2 readout est. (NCT04771871)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: MicroRNA Profiles
  in Triple Negative Breast Cancer\nEstimated primary completion: March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04771871
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02455141-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epirubicin: Phase 3 readout est. (NCT02455141)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: Adjuvant Treatmen
 t of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cance
 r\nEstimated primary completion: March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02455141
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06179303)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Functional Imaging in Prediction of Response to Abemacicli
 b for Advanced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEs
 timated primary completion: 1 March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06179303)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Functional Imaging in Prediction of Response to Abemaciclib 
 for Advanced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEsti
 mated primary completion: 1 March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06179303)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Functional Imaging in Prediction of Response to Abemaciclib for Advan
 ced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEstimated pri
 mary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/anastrozole#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06179303)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Functional Imaging in Prediction of Response to Abemacicli
 b for Advanced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEs
 timated primary completion: 1 March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Letrozole: Phase 2 readout est. (NCT06179303)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Functional Imaging in Prediction of Response to Abemaciclib for Advance
 d Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEstimated prima
 ry completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06179303
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005882-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07005882)
DESCRIPTION:Elacestrant\, phase 2\, Breast Cancer.\nStudy: Hormonal Recepto
 r (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preopera
 tive ELacestrant and PULSAR Radiotherapy\nEstimated primary completion: 1 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elacestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7005882
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Exemestane: Phase 2 readout est. (NCT06179303)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Functional Imaging in Prediction of Response to Abemaciclib for Advanc
 ed Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEstimated prim
 ary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05172518-2272@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Utidelone: Phase 3 readout est. (NCT05172518)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-neg
 ative Locally Advanced or Metastatic Breast Cancer\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /utidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05172518
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05172518-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05172518)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-
 negative Locally Advanced or Metastatic Breast Cancer\nEstimated primary c
 ompletion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05172518
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00585507-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT00585507)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Efficacy and Safety of 500mg of Fulvestrant\nEstimated pri
 mary completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT00585507
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548127-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05548127)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: TACTIVE-U: A Study to Learn About the Study Medicine (Ve
 pdegestrant) When Given With Other Medicines in People With Advanced or Me
 tastatic Breast Cancer (Sub-Study A)\nEstimated primary completion: 24 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0554
 8127
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548127-9103@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Veppanu (Vepdegestrant): Phase 1/2 readout est. (NCT05548127)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: TACTIVE-U: A Study to Learn About the Study Medicine (V
 epdegestrant) When Given With Other Medicines in People With Advanced or M
 etastatic Breast Cancer (Sub-Study A)\nEstimated primary completion: 24 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vepdegestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5548127
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113964-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Olaparib: Phase 2 readout est. (NCT07113964)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer 
 Patients With Homologous Recombination Deficiency (HRD)\nEstimated primary
  completion: 30 March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07113964
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04595565-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04595565)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sacituzumab Govitecan in Primary HER2-negative Breast Cance
 r\nEstimated primary completion: 30 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04595565
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04595565-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04595565)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer\nEstima
 ted primary completion: 30 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04595565
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632405-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06632405)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: A Trial of Ca
 mrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurre
 nt TNBC\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06632405
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510465-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06510465)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Thera
 py With Weekly Utidelone Combined With Cisplatin for Patients With Breast 
 Cancer (NeoURANIA)\nEstimated primary completion: 31 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06510465
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03990896-2243@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Talazoparib: Phase 2 readout est. (NCT03990896)
DESCRIPTION:Talazoparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Evaluation of Talazoparib\, a PARP Inhibitor\, in Patients With Somat
 ic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial\n
 Estimated primary completion: 31 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03990896
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588545-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT04588545)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: R
 adiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ B
 reast Leptomeningeal Disease\nEstimated primary completion: April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04588545
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03964532-2243@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT03964532)
DESCRIPTION:Talazoparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: TALAVE: Induction Talazoparib Followed by Combination of Talazopari
 b and Avelumab in Advanced Breast Cancer\nEstimated primary completion: Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 64532
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172127-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06172127)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresect
 able Locally Recurrent or Metastatic Breast Cancer\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 rastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06172127
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for B
 reast Cancer\nEstimated primary completion: April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06409390)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for 
 Breast Cancer\nEstimated primary completion: April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for 
 Breast Cancer\nEstimated primary completion: April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cance
 r\nEstimated primary completion: April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07426822-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capivasertib: Phase 2 readout est. (NCT07426822)
DESCRIPTION:Capivasertib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Rash & Diarrhea Prophylaxis With Capivasertib\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capivasertib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07426822
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-9029@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06409390)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for Br
 east Cancer\nEstimated primary completion: April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06409390)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for 
 Breast Cancer\nEstimated primary completion: April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07426822-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07426822)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Rash & Diarrhea Prophylaxis With Capivasertib\nEstimated p
 rimary completion: April 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07426822
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sequential Therapies Modeled on Evolutionary Dynamics for Breast Can
 cer\nEstimated primary completion: April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279364-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06279364)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of SKB264 Versus Investigator's Choice Chemotherapy in Patients With U
 nresectable Recurrent or Metastatic Triple-Negative Breast Cancer\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06279364
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04540692-9029@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT04540692)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Evaluation of Sequencing of Anthracyclines and Taxanes for L
 ocally Advanced HER2-negative Breast Cancer\nEstimated primary completion:
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxe
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 540692
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05696626-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05696626)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Evaluation of Lasofoxifene Combined With Abemaciclib Compa
 red With Fulvestrant Combined With Abemaciclib in Locally Advanced or Meta
 static ER+/HER2- Breast Cancer With an ESR1 Mutation\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05696626
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319873-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05319873)
DESCRIPTION:Ribociclib\, phase 1/2\, Breast Cancer.\nStudy: Ribociclib\, Tu
 catinib\, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
 \nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05319873
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319873-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT05319873)
DESCRIPTION:Tucatinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: Ri
 bociclib\, Tucatinib\, and Trastuzumab for the Treatment of HER2 Positive 
 Breast Cancer\nEstimated primary completion: 1 April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05319873
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319873-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05319873)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, Breast Cancer.\nStudy: Rib
 ociclib\, Tucatinib\, and Trastuzumab for the Treatment of HER2 Positive B
 reast Cancer\nEstimated primary completion: 1 April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05319873
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986071-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05986071)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: I/II Phase Study Evaluating M1774 in Combination With Fu
 lvestrant in HR+ and HER2- Advanced Breast Cancers\nEstimated primary comp
 letion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05986071
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06407310-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06407310)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Pe
 mbrolizumab\, Carboplatin and Paclitaxel in Triple-negative Breast Cancer\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06407310
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468061-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04468061)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Sacituzumab Go
 vitecan +/- Pembrolizumab in Metastatic TNBC\nEstimated primary completion
 : 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04468061
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468061-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04468061)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Sacitu
 zumab Govitecan +/- Pembrolizumab in Metastatic TNBC\nEstimated primary co
 mpletion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04468061
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501704-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05501704)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: ETHAN - ET for Male BC\nEstimated primary completion: 1 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 01704
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501704-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT05501704)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: ETHAN - ET for Male BC\nEstimated primary completion: 1 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-sol
 tamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05501704
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501704-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05501704)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ETHAN - ET for Male BC\nEstimated primary completion: 1 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05501704
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01953588-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT01953588)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, Breast Cancer.\nStudy: Fulve
 strant and/or Anastrozole in Treating Postmenopausal Patients With Stage I
 I-III Breast Cancer Undergoing Surgery\nEstimated primary completion: 1 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT019
 53588
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Olaparib: Phase 3 readout est. (NCT04421963)
DESCRIPTION:Olaparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Roll Over StudY for Patients Who Have Completed a Previous Oncology Stud
 y With Olaparib\nEstimated primary completion: 6 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04421963
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04965766-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270411
DTEND;VALUE=DATE:20270412
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT04965766)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Patritumab Deruxtecan (U3-1402) in Unresectable Locally Adv
 anced or Metastatic Breast Cancer\nEstimated primary completion: 11 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deru
 xtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04965766
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06247995-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06247995)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Phase I/II\, Dose Finding and Optimization Study of [177Lu]Lu-Ne
 oB in Combination With Capecitabine in Patients With GRPR+\, ER+\, HER2- M
 etastatic Breast Cancer After Progression on Previous Endocrine Therapy in
  Combination With a CDK4/6 Inhibitor.\nEstimated primary completion: 14 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 247995
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139470-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07139470)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, Breast Cancer.\nStudy: Sa
 cituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast
  Cancer\nEstimated primary completion: 15 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07139470
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04614194-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04614194)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Singl
 e Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaci
 clib\nEstimated primary completion: 15 April 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04614194
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05774951-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05774951)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years
  of Standard Adjuvant Endocrine Therapy\nEstimated primary completion: 20 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camizestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05774951
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02414269-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02414269)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Malignant Pleural Disease Treated With Autologous T Cells Genetic
 ally Engineered to Target the Cancer-Cell Surface Antigen Mesothelin\nEsti
 mated primary completion: 30 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT02414269
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for 
 HER2-positive Breast Cancer\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 900206
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cance
 r\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05900206
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cance
 r\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05900206
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101096-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05101096)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of Sacituzumab Govitecan (SG) in Japanese Participa
 nts With Advanced Solid Tumors\nEstimated primary completion: May 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05101
 096
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06665178-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06665178)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Genomic and Transcriptomic Predictors of Sequential SG Sens
 itivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer\nEstimated pr
 imary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06665178
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trast
 uzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-B
 reast09)\nEstimated primary completion: 3 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trastuzumab and P
 ertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)\nEs
 timated primary completion: 3 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894239-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT05894239)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, Breast Cancer.\nStudy: A Study
  to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phe
 sgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-
 Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer\nEstima
 ted primary completion: 3 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05894239
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428396-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06428396)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER
 2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)\nEstimated primary
  completion: 5 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06428396
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04305834-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04305834)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Abemaciclib and Endocrine Therapy in Older Patients With B
 reast Cancer.\nEstimated primary completion: 21 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04305834
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2090@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Saruparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer A
 gents in Patients With Advanced Solid Malignancies\nEstimated primary comp
 letion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 saruparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04644068
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Etcamah (Camizestrant): Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Etcamah (Camizestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AZD5305 as Monotherapy and in Combination With 
 Anti-cancer Agents in Patients With Advanced Solid Malignancies\nEstimated
  primary completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/camizestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005583-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Olaparib: Phase 2 readout est. (NCT07005583)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Clinical Study of Q
 L1706 in Combination With Olaparib for the Treatment of Patients With Prev
 iously Treated Homologous Recombination Repair-Deficient Recurrent or Meta
 static Triple-Negative Breast Cancer\nEstimated primary completion: 30 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07005583
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973525-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06973525)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: This Study Ai
 ms to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Impl
 ementing a Dynamic Monitoring-guided Treatment Strategy.\nEstimated primar
 y completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06973525
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973525-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06973525)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: This
  Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cance
 r by Implementing a Dynamic Monitoring-guided Treatment Strategy.\nEstimat
 ed primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06973525
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973525-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06973525)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive 
 Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strate
 gy.\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06973525
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974604-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06974604)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Preventing Dato-DXd Associated Stomatitis With Dexamethaso
 ne Mouthwash\, TROPION-DM\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069746
 04
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892693-2243@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Talazoparib: Phase 2 readout est. (NCT04892693)
DESCRIPTION:Talazoparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Talazoparib in Advanced Breast Cancer Patients With Homologous Recomb
 inant Deficiency\nEstimated primary completion: 31 May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04892693
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05095207-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05095207)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Abemaciclib in Combination With Bicalutamide for Androge
 n Receptor-positive\, HER2-negative Metastatic Breast Cancer\nEstimated pr
 imary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05095207
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546686-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03546686)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Peri-Operative
  Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negati
 ve Breast Cancer\nEstimated primary completion: June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03546686
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04920708-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04920708)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant\, Ipatasertib and CDK4/6 Inhibition in Metasta
 tic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04920708
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04920708-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04920708)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Fulvestrant\, Ipatasertib and CDK4/6 Inhibition in Metastat
 ic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\nEstimated p
 rimary completion: June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04920708
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07367178-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07367178)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Sacituzumab Govitecan With Atropine to Improve Tol
 erability in Advanced TNBC and HR+/HER2- Breast Cancer\nEstimated primary 
 completion: June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07367178
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731153-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT06731153)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: JAK1 Inhib
 itor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC\nEstimated p
 rimary completion: June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06731153
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353997-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06353997)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant IN
 BRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06353997
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117630-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07117630)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: An Open-Label\, Bayesian Adaptive Phase II Clinical Study 
 in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07117630
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Sacit
 uzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Ch
 oice in Patients With Triple Negative Breast Cancer Who Have Residual Inva
 sive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 Optim
 ICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05633654
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice in Patients With Triple Negative Breast Cancer Who Have Resid
 ual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-
 65 OptimICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05633654
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03598257-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Olaparib: Phase 2 readout est. (NCT03598257)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Radiation Therapy With or Without Olaparib in Treating Patients With Inf
 lammatory Breast Cancer\nEstimated primary completion: 1 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03598257
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458674-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05458674)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Tucatinib+Trastuzu
 mab+Eribulin in HER2+ MBC\nEstimated primary completion: 1 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05458674
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458674-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT05458674)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: Tucatinib+
 Trastuzumab+Eribulin in HER2+ MBC\nEstimated primary completion: 1 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 58674
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975475-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06975475)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: SHR-A1811 and
  THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Bra
 in Metastases\nEstimated primary completion: 1 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06975475
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368543-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07368543)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic B
 reast Cancer\nEstimated primary completion: 1 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07368543
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368543-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07368543)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic 
 Breast Cancer\nEstimated primary completion: 1 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07368543
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975462-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06975462)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Phase II Study of SHR-A1811 Combined With Radiotherapy in
  HER2-positive and HER2-low Breast Cancer Brain Metastases\nEstimated prim
 ary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06975462
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975475-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06975475)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: SHR-A1
 811 and THPy in First or Second Line for HER2 Positive Advanced Breast Can
 cer Brain Metastases\nEstimated primary completion: 1 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06975475
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832202-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06832202)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Study of HLX22 in Combination With Trastuzumab 
 Deruxtecan in HER2-low\, Hormone Receptor Positive Locally Advanced or Met
 astatic Breast Cancer Patients\nEstimated primary completion: 1 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6832202
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775236-2211@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:CPO301: Phase 1/2 readout est. (NCT06775236)
DESCRIPTION:CPO301\, phase 1/2\, Breast Cancer.\nStudy: Clinical Trial of S
 YS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other So
 lid Tumors\nEstimated primary completion: 15 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06775236
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to 
 Evaluate the Safety\, and Tolerability of AZD8421 Alone or in Combination 
 in Participants With Selected Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A First-in-human Dose Escalation and Expansion Study to Evaluate the
  Safety\, and Tolerability of AZD8421 Alone or in Combination in Participa
 nts With Selected Advanced or Metastatic Solid Tumors\nEstimated primary c
 ompletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06188520
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Etcamah (Camizestrant): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Etcamah (Camizestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to 
 Evaluate the Safety\, and Tolerability of AZD8421 Alone or in Combination 
 in Participants With Selected Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/camizestrant#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to E
 valuate the Safety\, and Tolerability of AZD8421 Alone or in Combination i
 n Participants With Selected Advanced or Metastatic Solid Tumors\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Study of JSKN016 Combination Therapy in Inoperable Locally Advanc
 ed or Metastatic HER2-Negative Breast Cancer\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06942234
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-2147@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JSKN016: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:JSKN016\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or 
 Metastatic HER2-Negative Breast Cancer\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jskn016#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0694223
 4
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:Eribulin mesylate\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: Study of JSKN016 Combination Therapy in Inoperable Locally Ad
 vanced or Metastatic HER2-Negative Breast Cancer\nEstimated primary comple
 tion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ribulin-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06942234
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993844-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06993844)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase 1/2 Study of ETX-636 in Participants With Advanced
  Solid Tumors\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06993844
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Study of JSKN016 Combination Therapy in Inoperable Locally Advance
 d or Metastatic HER2-Negative Breast Cancer\nEstimated primary completion:
  30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capeci
 tabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06942234
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616987-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06616987)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Preven
 tion of Sacituzumab Govitecan-related Neutropenia in Patients With Metasta
 tic Triple Negative Breast Cancer\nEstimated primary completion: 30 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06616987
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878625-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06878625)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: A Mult
 icenter\, Prospective\, Cohort Study of Trop-2 ADC Combination Therapy for
  Advanced Triple-negative Breast Cancer\nEstimated primary completion: 30 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzuma
 b-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06878625
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498478-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07498478)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Efficacy and Safety of Tinengotinib Tablets Combined With 
 Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recu
 rrent or Metastatic Breast Cancer Who Have Failed Prior Treatment\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07498478
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498478-9067@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tinengotinib: Phase 2 readout est. (NCT07498478)
DESCRIPTION:Tinengotinib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestran
 t Injection in Patients With HR Positive and HER-2 Negative Recurrent or M
 etastatic Breast Cancer Who Have Failed Prior Treatment\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tinengotinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07498478
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923542-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04923542)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: SRS & Abemaciclib w/wo Imlunestrant in the Management of
  HR+/HER2- Breast CA Brain Metastases\nEstimated primary completion: July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0492354
 2
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735080-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05735080)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Open-Label Study to Evaluate the Safety\, Tolerability\,
  PK\, and Efficacy of INX-315 in Patients With Advanced Cancer\nEstimated 
 primary completion: July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05735080
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735080-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05735080)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Open-Label Study to Evaluate the Safety\, Tolerability\,
  PK\, and Efficacy of INX-315 in Patients With Advanced Cancer\nEstimated 
 primary completion: July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05735080
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04841148-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04841148)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Avelumab or Hydroxychloroquine With or Without Palbociclib 
 to Eliminate Dormant Breast Cancer\nEstimated primary completion: July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04841148
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528898-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07528898)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Neo
 adjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer
 : An Exploratory Clinical Study.\nEstimated primary completion: July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07528898
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528898-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07528898)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Br
 east Cancer: An Exploratory Clinical Study.\nEstimated primary completion:
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07528898
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188246-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07188246)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant\, 
 SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy
  in Breast Cancer\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07188246
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05388149-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Neratinib: Phase 2 readout est. (NCT05388149)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Kadc
 yla And Neratinib for Interception of HER2+ Breast Cancer With Molecular R
 esidual Disease\nEstimated primary completion: July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05388149
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467772-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07467772)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ph 2 Elacestrant in ER Positive Uterine Sarcomas\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07467772
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04711109-11057@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Denosumab (Xgeva): Phase 3 readout est. (NCT04711109)
DESCRIPTION:Denosumab (Xgeva)\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Studying the Effect of Denosumab on Preventing Breast Cancer in
  Women With a BRCA1 Germline Mutation\nEstimated primary completion: July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-xgeva
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047
 11109
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071337-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07071337)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SKB264 Versus Investigator's Choice of Chemoth
 erapy in Subjects With Unresectable Locally Advanced\, Relapsed\, or Metas
 tatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07071337
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Pembrolizumab\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and 
 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician'
 s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or M
 etastatic Breast Cancer (MK-2870-010)\nEstimated primary completion: 11 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 312176
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single 
 Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of 
 Physician's Choice in Participants With HR+/HER2- Unresectable Locally Adv
 anced or Metastatic Breast Cancer (MK-2870-010)\nEstimated primary complet
 ion: 11 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06312176
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04301375-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04301375)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Omi
 ssion of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk
  HER2positive Breast Cancer With High HER2 Addiction and a Complete Respon
 se Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)\n
 Estimated primary completion: 15 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04301375
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04301375-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04301375)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Omission of Surgery and Sentinel Lymph Node Dissection in Clinical
 ly Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Comp
 lete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELP
 IS Trial)\nEstimated primary completion: 15 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04301375
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Everolimus: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07062965)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Learn About the Study Medicine Called PF-072481
 44 in Combination With Fulvestrant in People With HR-positive\, HER2-negat
 ive Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line
  of Treatment.\nEstimated primary completion: 22 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Exemestane: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9082@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Prifetrastat: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Prifetrastat\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-07248144 in Comb
 ination With Fulvestrant in People With HR-positive\, HER2-negative Advanc
 ed or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatm
 ent.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/prifetrastat#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/prifetrastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Study of Dato-DXd With or Without Durvalumab Compared With Investig
 ator's Choice of Chemotherapy in Combination With Pembrolizumab in Patient
 s With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-ne
 gative Breast Cancer (TROPION-Breast05)\nEstimated primary completion: 28 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06103864
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739485-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Epirubicin: Phase 1/2 readout est. (NCT07739485)
DESCRIPTION:Epirubicin\, phase 1/2\, Breast Cancer.\nStudy: Paclitaxel Oral
  Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Fin
 ding Study\nEstimated primary completion: 30 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07739485
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439771-1982@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06439771)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Phase 2 Study to Evaluate the Efficacy\, Safety and Pharm
 acokinetics of YL202 in Patients With BC\nEstimated primary completion: 30
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beruzatat
 ug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06439771
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258108-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07258108)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Sac-TMT Plus KL-A167 in PD-L1+\, HR+/HER2- Metastatic Bre
 ast Cancer After CDK4/6 Inhibitors\nEstimated primary completion: 30 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07258108
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258108-2581@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07258108)
DESCRIPTION:Tagitanlimab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sac-TMT Plus KL-A167 in PD-L1+\, HR+/HER2- Metastatic Breast Cancer 
 After CDK4/6 Inhibitors\nEstimated primary completion: 30 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07258108
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03304080-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Anastrozole: Phase 1/2 readout est. (NCT03304080)
DESCRIPTION:Anastrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Anastrozole\, Palbociclib\, Trastuzumab and Pertuzumab in HR-positi
 ve\, HER2-positive Metastatic Breast\nEstimated primary completion: 31 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03304
 080
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03304080-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT03304080)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Anastrozole\, Palbociclib\, Trastuzumab and Pertuzumab in
  HR-positive\, HER2-positive Metastatic Breast\nEstimated primary completi
 on: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pal
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03304080
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739511-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT07739511)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: P
 aclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy
 : A Dose-Finding Study\nEstimated primary completion: 31 July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07739511
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07054190)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: A Study to Test I
 navolisib Treatments in Participants With Early-Stage\, PIK3CA-Mutated Bre
 ast Cancer\nEstimated primary completion: 31 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07054190
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07054190)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Study
  to Test Inavolisib Treatments in Participants With Early-Stage\, PIK3CA-M
 utated Breast Cancer\nEstimated primary completion: 31 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07054190
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04055493-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ribociclib: Phase 3 readout est. (NCT04055493)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Adj. Marker-adjus
 ted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Interm
 ediate Risk\, HR+/HER2- EBC\nEstimated primary completion: 31 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04055493
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab Emtansine: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Trastuzumab Emtansine\, phase 1/2\, Breast Cancer.\nStudy: A St
 udy to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or
  in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other
  Anticancer Therapies in Adult Participants With Locally Advanced or Metas
 tatic Solid Tumor Malignancies\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 081609
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386108-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05386108)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of Abemaciclib and Elacestrant in Participants Wit
 h Brain Metastasis Due to ER+/HER-2- Breast Cancer\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05386108
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386108-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05386108)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Abemaciclib and Elacestrant in Participants With Brain Met
 astasis Due to ER+/HER-2- Breast Cancer\nEstimated primary completion: Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 86108
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027268-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06027268)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Phase II Trial
  of Trilaciclib\, Pembrolizumab\, Gemcitabine and Carboplatin in Metastati
 c Triple-Negative Breast Cancer\nEstimated primary completion: August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06027268
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05020860-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05020860)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Correlation of
  Clinical Response to Pathologic Response in Patients With Early Breast Ca
 ncer\nEstimated primary completion: August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05020860
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299409-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07299409)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: First-
 Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Ca
 ncer Patients.\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07299409
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05020860-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05020860)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Cor
 relation of Clinical Response to Pathologic Response in Patients With Earl
 y Breast Cancer\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05020860
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05181033-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Letrozole: Phase 2 readout est. (NCT05181033)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast 
 Cancer\, Post Progression on Al + CDK4/6 Inhibitor\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05181033
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024173-11068@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07024173)
DESCRIPTION:HRS-8080\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Loc
 ally Advanced and Metastatic Breast Cancer\nEstimated primary completion: 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 24173
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973319-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT04973319)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Trastuzumab Combi
 ned With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuv
 ant Therapy\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04973319
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HER2-Positive Breast Cance
 r.\nStudy: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in
  Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positiv
 e Advanced Solid Tumors\nEstimated primary completion: 31 August 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05593
 094
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: A
  Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participant
 s With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced S
 olid Tumors\nEstimated primary completion: 31 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05593094
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab Emtansine: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Trastuzumab Emtansine\, phase 1/2\, HER2-Positive Breast Cancer
 .\nStudy: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in 
 Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  Advanced Solid Tumors\nEstimated primary completion: 31 August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0559309
 4
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-11326@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bizrolertinib: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Bizrolertinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy
 : A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Particip
 ants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advance
 d Solid Tumors\nEstimated primary completion: 31 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bizrolertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05593094
URL:https://assetmemo.bio/drug/bizrolertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499999-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07499999)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Randomized Double-Blind Phase II Trial of Baby Exemestane Ve
 rsus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cance
 r\nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07499999
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499999-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Exemestane: Phase 2 readout est. (NCT07499999)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby 
 Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer\nEstimat
 ed primary completion: 31 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07499999
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05693766-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05693766)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort\nEstimat
 ed primary completion: 31 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05693766
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06298084-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06298084)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Dose-Expansion Modular Study To Explore the Safety\, Tole
 rability\, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinatio
 ns in Patients With Inoperable Advanced Breast Cancer (ABC) After Progress
 ion on T-DXd\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06298084
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06298084-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06298084)
DESCRIPTION:Olaparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Dose-Expansion Modular Study To Explore the Safety\, Tolerability\, an
 d Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patient
 s With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd\
 nEstimated primary completion: September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06298084
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150208-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07150208)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd With or Without Bevacizumab for HER2-low Breast Canc
 er With Brain Metastasis\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715
 0208
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180160-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07180160)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-
 positive\, HER2-negative Advanced Breast Cancer\nEstimated primary complet
 ion: September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07180160
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923527-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06923527)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Circulating Tumor DNA\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06923527
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382948-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Everolimus: Phase 3 readout est. (NCT06382948)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant + Everolimus in Patients ER+/HER2-\, ESR1mut\, Advanced Br
 east Cancer Progressing to ET and CDK4/6i.\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/evero
 limus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06382948
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Panc
 reatic and Breast Cancer\nEstimated primary completion: 1 September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 825753
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancr
 eatic and Breast Cancer\nEstimated primary completion: 1 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0782
 5753
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-2044@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Pan
 creatic and Breast Cancer\nEstimated primary completion: 1 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07825753
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Panc
 reatic and Breast Cancer\nEstimated primary completion: 1 September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 825753
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Protei
 n-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Canc
 er\nEstimated primary completion: 1 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07825753
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04985266-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04985266)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Trial of Early Detection of Molecular Relapse With Circu
 lating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant
  Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negat
 ive Breast Cancer\nEstimated primary completion: 1 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04985266
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04985266-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04985266)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial of Early Detection of Molecular Relapse With Circul
 ating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant 
 Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negati
 ve Breast Cancer\nEstimated primary completion: 1 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04985266
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of 
 Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without
  Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Bre
 ast03)\nEstimated primary completion: 1 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05629585
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05192798-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05192798)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Albumin-Bound
  Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of
  Relapsed or Metastatic TNBC\nEstimated primary completion: 10 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05192
 798
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601178-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07601178)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: QUEEN-APPLE: 
 A Single-Arm\, Multicenter\, Prospective Phase II Clinical Study of Iparom
 limab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochlorid
 e and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative 
 Breast Cancer\nEstimated primary completion: 15 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07601178
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-2090@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Saruparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Participa
 nts With Advanced/Metastatic Solid Malignancies\nEstimated primary complet
 ion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/saruparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05123482
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02955940)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: An Open-Label Study to Enable Continued Treatment Access for Subject
 s Previously Enrolled in Studies of Ruxolitinib\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02955940
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06318897-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06318897)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Open-label\, S
 ingle Center\, Single-arm\, Phase 2 Study of Neoadjuvant Pembrolizumab in 
 Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-
 T1cN0M0 Triple Negative Breast Cancer\nEstimated primary completion: 30 Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06318897
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393425-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07393425)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Neoad
 juvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Can
 cer\nEstimated primary completion: 30 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07393425
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393425-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07393425)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Trast
 uzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07393425
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07125950-11068@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HRS-8080: Phase 2 readout est. (NCT07125950)
DESCRIPTION:HRS-8080\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/hrs-8080#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07125950
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514054-9192@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Inluriyo (Imlunestrant): Phase 3 readout est. (NCT05514054)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant Versus Standard Endocrine Therapy in Participants With
  Early Breast Cancer\nEstimated primary completion: October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05514054
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05982678-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05982678)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Basket Study for Oligo-metastatic Breast Cancer\nEstimated
  primary completion: 1 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05982678
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950945-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT05950945)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormon
 e Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 M
 etastatic Breast Cancer\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05950
 945
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05090358-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05090358)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Preventing High Blood Sugar in People Being Treated for Metast
 atic Breast Cancer\nEstimated primary completion: 8 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05090358
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05090358-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05090358)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Preventing High Blood Sugar in People Being Treated for Me
 tastatic Breast Cancer\nEstimated primary completion: 8 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05090358
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03707340-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT03707340)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study of Flibanserin in Breast Cancer Survivors on Tamoxif
 en or Aromatase Inhibitors\nEstimated primary completion: 14 October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03707
 340
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06845319-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06845319)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: NeoCARD: Anthr
 acycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Can
 cer Patients\nEstimated primary completion: 20 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06845319
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966453-2454@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06966453)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: A Study of Disitamab Vedotin in Adults With HER2 Expressing A
 dvanced Breast Cancer\nEstimated primary completion: 25 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06966453
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06612814)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therap
 y in HR+/ HER2-Advanced Breast Cancer\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6612814
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT06612814)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ H
 ER2-Advanced Breast Cancer\nEstimated primary completion: 30 October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06612814
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04266249)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: CompassHER2-p
 CR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery C
 hemo and Targeted Therapy\nEstimated primary completion: 31 October 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04266249
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04266249)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: CompassHER2-pCR: 
 Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo
  and Targeted Therapy\nEstimated primary completion: 31 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04266249
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04266249)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Compas
 sHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-su
 rgery Chemo and Targeted Therapy\nEstimated primary completion: 31 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-em
 tansine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04266249
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04563507-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04563507)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Combined Immunotherapies in Metastatic ER+ Breast Cancer\nE
 stimated primary completion: 31 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04563507
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04563507-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Letrozole: Phase 2 readout est. (NCT04563507)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Combined Immunotherapies in Metastatic ER+ Breast Cancer\nEstimated pri
 mary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04563507
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06110793-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06110793)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of Lenvatinib\, Pembrolizumab\, and Fulvestrant 
 in People With Breast Cancer\nEstimated primary completion: November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06110793
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035745-2243@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT05035745)
DESCRIPTION:Talazoparib\, phase 1/2\, Breast Cancer.\nStudy: Selinexor & Ta
 lazoparib in Advanced Refractory Solid Tumors\; Advanced/Metastatic Triple
  Negative Breast Cancer (START)\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05035745
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276880-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07276880)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Preoperative C
 hemotherapy\, Pembrolizumab and Low or High Dose RADiation in an Expansion
  Cohort of Node(+)\, Triple Negative Breast Cancer\nEstimated primary comp
 letion: November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07276880
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203378-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07203378)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Nurturing Exercise Routine for Greater Improvement in Zest
  and Energy on Enhertu\nEstimated primary completion: November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720337
 8
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05748834-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05748834)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Study of Tucatinib
  and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 P
 ositive (HER2+) Metastatic Breast Cancer\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tucatini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 748834
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299890-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07299890)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: An Exploratory St
 udy of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exem
 estane as Neoadjuvant Therapy for Triple-Positive Breast Cancer\nEstimated
  primary completion: 1 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07299890
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299890-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT07299890)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, Breast Cancer.\nStudy: An Exp
 loratory Study of Pertuzumab and Trastuzumab in Combination With Palbocicl
 ib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
 \nEstimated primary completion: 1 November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07299890
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299890-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Exemestane: Phase 2 readout est. (NCT07299890)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: An Exploratory St
 udy of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exem
 estane as Neoadjuvant Therapy for Triple-Positive Breast Cancer\nEstimated
  primary completion: 1 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07299890
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04862663)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastat
 ic HR+/HER2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 
 1 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abem
 aciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04862663
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ribociclib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2-
  Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862663
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Capivasertib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER
 2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862
 663
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT04862663)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastati
 c HR+/HER2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1
  November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04862663
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220135-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07220135)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trial of Neoadjuv
 ant THP vs TCHP for HER2-Amplified/Positive Breast Cancer\nEstimated prima
 ry completion: 14 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07220135
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333937-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Neratinib: Phase 2 readout est. (NCT07333937)
DESCRIPTION:Neratinib\, phase 2\, Breast Cancer.\nStudy: Neratinib Combined
  With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breas
 t Cancer\nEstimated primary completion: 20 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07333937
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333937-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07333937)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: Neratinib 
 Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanc
 ed Breast Cancer\nEstimated primary completion: 20 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07333937
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333937-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07333937)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Nerat
 inib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ A
 dvanced Breast Cancer\nEstimated primary completion: 20 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07333937
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330544-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271125
DTEND;VALUE=DATE:20271126
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07330544)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Clinical Study Evaluating Entinostat With or Wi
 thout Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -
 Positive\, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Adva
 nced Breast Cancer That Relapsed or Progressed After Endocrine Therapy\nEs
 timated primary completion: 25 November 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07330544
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05826964-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05826964)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Levels of Circulating Tumor DNA as a Predictive Marker for
  Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast 
 Cancer\nEstimated primary completion: 30 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05826964
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capivasertib: Phase 3 readout est. (NCT06764186)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combinatio
 n With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relaps
 ed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Pr
 actice in Spain\nEstimated primary completion: 30 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06764186)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in 
 Combination With Fulvestrant in Patients With Advanced Breast Cancer Who H
 ave Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World C
 linical Practice in Spain\nEstimated primary completion: 30 November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336771-2147@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JSKN016: Phase 1/2 readout est. (NCT07336771)
DESCRIPTION:JSKN016\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic H
 R-Positive\, HER2-Negative Breast Cancer\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jskn016#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 6771
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336771-9088@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taragarestrant: Phase 1/2 readout est. (NCT07336771)
DESCRIPTION:Taragarestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: JSKN016 in Combination With D-0502 for Locally Advanced or Metas
 tatic HR-Positive\, HER2-Negative Breast Cancer\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 aragarestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07336771
URL:https://assetmemo.bio/drug/taragarestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Trial of HRS-6209 in Combination With Other Antitumor 
 Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients
  With Advanced Solid Tumors\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in 
 Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advance
 d Solid Tumors\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9146@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SHR-6209: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:SHR-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in B
 reast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/shr-6209#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9181@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-6209: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:HRS-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in B
 reast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-6209#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-11068@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-8080: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:HRS-8080\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in B
 reast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07935317)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: A Stu
 dy of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Par
 ticipants With PIK3CA-Mutated Early Breast Cancer\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07935317
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07935317)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: A Study of Tersol
 isib (LY4064809) and Abemaciclib With Hormone Therapies in Participants Wi
 th PIK3CA-Mutated Early Breast Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 5317
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-9063@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tersolisib: Phase 2 readout est. (NCT07935317)
DESCRIPTION:Tersolisib\, phase 2\, Breast Cancer.\nStudy: A Study of Tersol
 isib (LY4064809) and Abemaciclib With Hormone Therapies in Participants Wi
 th PIK3CA-Mutated Early Breast Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tersolisib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 5317
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582538-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05582538)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Restoring Sen
 sitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploi
 ting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05582538
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523857-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04523857)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: ABemacicliB or Abemaciclib and HydroxYchloroquine to Targe
 t Minimal Residual Disease in Breast Cancer\nEstimated primary completion:
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abema
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04523857
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365788-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06365788)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Bical
 utamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-posi
 tive Triple-negative Breast Cancer\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063657
 88
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007559-3357@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Evorpacept: Phase 2 readout est. (NCT07007559)
DESCRIPTION:Evorpacept\, phase 2\, HER2-Positive Breast Cancer.\nStudy: ASP
 EN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemot
 herapy in Metastatic HER2-Positive Breast Cancer\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 evorpacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07007559
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007559-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07007559)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: ASPEN-09-0
 3: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy 
 in Metastatic HER2-Positive Breast Cancer\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eribuli
 n-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07007559
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227233-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07227233)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Artificial Intelligence and Machine Learning to Guide CDK4
 /6 Inhibitor Rechallenge in Breast Cancer.\nEstimated primary completion: 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulves
 trant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227233
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265428-2448@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06265428)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265428
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196774-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07196774)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoa
 djuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast
  Cancer\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196774
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05795101-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05795101)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: TRUDI: TDXD+Durva in HER2+/Low IBC\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05795101
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955170-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271219
DTEND;VALUE=DATE:20271220
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05955170)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tuca
 tinib in Combination With Oral Etoposide andTrastuzumab in Patients With M
 etastatic HER2+ Breast Cancer\nEstimated primary completion: 19 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05955170
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745257-9077@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07745257)
DESCRIPTION:Culmerciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HE
 R2-Negative Metastatic Breast Cancer With Brain Metastases\nEstimated prim
 ary completion: 28 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07745257
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07427394-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07427394)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study to Evaluate the Safety and Tolerability of Camizestr
 ant in Combination With Atirmociclib in Women With Advanced Breast Cancer\
 nEstimated primary completion: 28 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/camizestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07427394
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07427394-9131@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT07427394)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Evaluate the Safety and Tolerability of Camizestrant in Com
 bination With Atirmociclib in Women With Advanced Breast Cancer\nEstimated
  primary completion: 28 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07427394
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2201@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A 
 Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy 
 in Participants With HER2-positive Breast Cancer\nEstimated primary comple
 tion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102381
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A P
 hase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy i
 n Participants With HER2-positive Breast Cancer\nEstimated primary complet
 ion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07102381
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647016-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07647016)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan Plus ivonescImab for Hormone Recept
 or-positive HER2 Negative Advanced Breast Cancer Study\nEstimated primary 
 completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07647016
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494448-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT07494448)
DESCRIPTION:Tucatinib\, phase 1/2\, Breast Cancer.\nStudy: Phase Ib/II Stud
 y of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced
  Breast Cancer\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07494448
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494448-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT07494448)
DESCRIPTION:Eribulin mesylate\, phase 1/2\, Breast Cancer.\nStudy: Phase Ib
 /II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive 
 Advanced Breast Cancer\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07494448
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281976-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07281976)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Breast Cancer.\nStudy: A Trial of 
 LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative B
 reast Cancer\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07281976
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608252-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05608252)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: VS-6766+Abema+Fulv in Met HR+/HER- BC\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05608252
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608252-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05608252)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: VS-6766+Abema+Fulv in Met HR+/HER- BC\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05608252
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04647916-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04647916)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Testing Sacituzumab Govitecan Therapy in Patients With HER2
 -Negative Breast Cancer and Brain Metastases\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 acituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04647916
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202316-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT03202316)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Atezolizumab\, Cobimetinib\, and Eribulin in Treating Patients 
 With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03202316
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capivasertib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Capivasertib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Targeted Therapy Directed by Genetic Testing in Treating Patients Wi
 th Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Myeloma (The
  MATCH Screening Trial)\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04567420-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04567420)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: DNA-g
 uided Second Line Adjuvant Therapy for High Residual Risk\, Estrogen Recep
 tor Positive\, HER-2 Negative Breast Cancer (DARE)\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04567420
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02465060)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating Pa
 tients With Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Mye
 loma (The MATCH Screening Trial)\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02465
 060
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04567420-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04567420)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, Breast Cancer.\nStudy: DNA-gu
 ided Second Line Adjuvant Therapy for High Residual Risk\, Estrogen Recept
 or Positive\, HER-2 Negative Breast Cancer (DARE)\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04567420
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-9075@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sapanisertib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Sapanisertib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Targeted Therapy Directed by Genetic Testing in Treating Patients Wi
 th Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Myeloma (The
  MATCH Screening Trial)\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sapanisertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849492-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06849492)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: HIM Typing Gu
 ides the Treatment of Advanced First-Line Triple-Negative Breast Cancer\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06849492
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862751-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07862751)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: US/PA/E Imagin
 g for Early Identification of Tumor Response in Patients With Stage II-III
  Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Che
 motherapy\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07862751
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849492-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06849492)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: HIM 
 Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast 
 Cancer\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06849492
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246317-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07246317)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Evaluation of Neo
 adjuvant Therapy With Trastuzumab\, Pertuzumab\, Docetaxel\, and QL1706 in
  Early or Locally Advanced HER2+ Breast Cancer\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07246317
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307287-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07307287)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early 
 or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective
 \, Open-Label\, Phase II Study\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07307287
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Fudan Univers
 ity Shanghai Cancer Center Breast Cancer Precision Platform Series Study- 
 Neoadjuvant Therapy\nEstimated primary completion: 31 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964906-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06964906)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant H
 igh-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chem
 otherapy for ER-Positive /HER2-Negative Breast Cancer\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06964906
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601440-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05601440)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-in
 hibitor Resistant ER+/HER2- Metastatic Breast Cancer\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05601440
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04090567-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT04090567)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Meta
 static Germline BRCA Mutated Breast Cancer\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ola
 parib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04090567
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Fuda
 n University Shanghai Cancer Center Breast Cancer Precision Platform Serie
 s Study- Neoadjuvant Therapy\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2239@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT05582499)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: Fudan University Shang
 hai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuva
 nt Therapy\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876557-2239@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT07876557)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: A Clinical Study to Ev
 aluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy
  in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/js207#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07876557
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Fud
 an University Shanghai Cancer Center Breast Cancer Precision Platform Seri
 es Study- Neoadjuvant Therapy\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402473-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07402473)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Optimize Neoadjuv
 ant Therapy in HER2-Positive Early-Stage Breast Cancer\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07402473
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2506@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Docetaxel (HB1801): Phase 2 readout est. (NCT05582499)
DESCRIPTION:Docetaxel (HB1801)\, phase 2\, HER2-Positive Breast Cancer.\nSt
 udy: Fudan University Shanghai Cancer Center Breast Cancer Precision Platf
 orm Series Study- Neoadjuvant Therapy\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxe
 l-hb1801#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05582499
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749588-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Everolimus: Phase 2 readout est. (NCT05749588)
DESCRIPTION:Everolimus\, phase 2\, Breast Cancer.\nStudy: FUSCC Refractory 
 TNBC Platform Study (FUTURE2.0)\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0574958
 8
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601440-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05601440)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-i
 nhibitor Resistant ER+/HER2- Metastatic Breast Cancer\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05601440
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014410-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07014410)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-posit
 ive and HER2-positive Advanced Breast Cancer\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 etrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07014410
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285382-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07285382)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Different Doses of Dalpicicl Combined With Letrozole in the First-line 
 Treatment of HR-positive\, HER2-negative Advanced Breast Cancer\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07285382
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014410-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07014410)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-pos
 itive and HER2-positive Advanced Breast Cancer\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07014410
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285382-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07285382)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Different Doses of Dalpicicl Combined With Letrozole in the First-lin
 e Treatment of HR-positive\, HER2-negative Advanced Breast Cancer\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07285382
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Fudan University Shanghai Cancer Center Breast Cancer Precision Pl
 atform Series Study- Neoadjuvant Therapy\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05582499
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749588-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05749588)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: FUSCC 
 Refractory TNBC Platform Study (FUTURE2.0)\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05749588
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Fudan University 
 Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoa
 djuvant Therapy\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964906-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06964906)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant High-
 Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemothe
 rapy for ER-Positive /HER2-Negative Breast Cancer\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/epirubicin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06964906
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9179@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anbenitamab repodatecan: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Anbenitamab repodatecan\, phase 2\, HER2-Positive Breast Cancer
 .\nStudy: Fudan University Shanghai Cancer Center Breast Cancer Precision 
 Platform Series Study- Neoadjuvant Therapy\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anb
 enitamab-repodatecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410169-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07410169)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Na
 b-paclitaxel-Induced Peripheral Neuropathy\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07410169
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461454-1982@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07461454)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: YL202 Versus Treatment of Physician's Choice in Patients Wi
 th HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7461454
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04400695-2454@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT04400695)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of RC48-ADC for the Treatment of Locally Advanced or Me
 tastatic Breast Cancer With Low Expression of HER2\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04400695
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109284-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07109284)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: SKB2
 64 Combined With KL-A167 Neoadjuvant Therapy for Early-stage\, High-risk E
 R+/HER2- Breast Cancer\nEstimated primary completion: January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0710928
 4
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235618-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07235618)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Entinostat in Combination With Fulvestrant for 
 the Treatment of Locally Advanced or Metastatic Breast Cancer\nEstimated p
 rimary completion: January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07235618
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05872204-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05872204)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Abemaciclib and Letrozole in Patients With Estrogen Recept
 or-positive Rare Ovarian Cancer\nEstimated primary completion: January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05872204
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832904-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06832904)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Neoa
 djuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Brea
 st Cancer (NEOTORCH-BREAST05)\nEstimated primary completion: January 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06832904
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05872204-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Letrozole: Phase 2 readout est. (NCT05872204)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive R
 are Ovarian Cancer\nEstimated primary completion: January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05872204
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05328440-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05328440)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Treat
 ment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2
 + Advanced Breast Cancer(DAP-Her-02)\nEstimated primary completion: 1 Janu
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 28440
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733233-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06733233)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: A Stu
 dy Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combina
 tion with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 
 Low-expressing Chinese Patients with Early-stage Breast Cancer\nEstimated 
 primary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06733233
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06176261-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06176261)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain 
 metAstaSEs\nEstimated primary completion: 1 January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06176261
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533826-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06533826)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or
  T-DXd: TRADE DXd\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06533826
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533826-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06533826)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or
  T-DXd: TRADE DXd\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06533826
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380646-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07380646)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: the Efficacy of L
 eucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Ear
 ly Breast Cancer\nEstimated primary completion: 1 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07380646
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158021-8458@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Goserelin: Phase 2 readout est. (NCT07158021)
DESCRIPTION:Goserelin\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Pe
 ri-menopausal Women With Breast Cancer\, OFS Trial\nEstimated primary comp
 letion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/goserelin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07158021
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Multi-mode Thermal Therapy Combined With Immunotherapy In 
 Patients With HER2-negative Breast Cancer With Liver Metastases\nEstimated
  primary completion: 15 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of Multi-mode Thermal Therapy Combined With Immunot
 herapy In Patients With HER2-negative Breast Cancer With Liver Metastases\
 nEstimated primary completion: 15 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Multi-mode Thermal Therapy Combined With Immunothe
 rapy In Patients With HER2-negative Breast Cancer With Liver Metastases\nE
 stimated primary completion: 15 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294508-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT07294508)
DESCRIPTION:Pertuzumab\, phase 2/3\, Breast Cancer.\nStudy: A Study to Eval
 uate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurr
 ent or Metastatic Breast Cancer\nEstimated primary completion: 15 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07294508
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366840-2454@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280116
DTEND;VALUE=DATE:20280117
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT07366840)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, HER2-Positive Breast Cancer.\nS
 tudy: RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Can
 cer Patients With Prior TOP1i-ADC Failure\nEstimated primary completion: 1
 6 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disit
 amab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07366840
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244874-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07244874)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: Sac-
 TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a
 /mTNBC\nEstimated primary completion: 30 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07244874
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\
 nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\nEstimated 
 primary completion: 31 January 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\
 nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of AVZO-021 in Patients With Advanced Solid Tumors\nEstimated p
 rimary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9111@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:AVZO-021: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:AVZO-021\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Study of AVZO-021 in Patients With Advanced Solid Tumors\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/avzo-021#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/avzo-021#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284836-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07284836)
DESCRIPTION:Nab-paclitaxel\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplati
 n (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients W
 ith Liver Metastases After Failure of Standard Therapy\nEstimated primary 
 completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07284836
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04457596-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tucatinib: Phase 3 readout est. (NCT04457596)
DESCRIPTION:Tucatinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: T-DM
 1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People
  With High Risk HER2-Positive Breast Cancer\, the CompassHER2 RD Trial\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04457596
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in
  Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast
  Cancer\nEstimated primary completion: February 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combinatio
 n in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEs
 timated primary completion: February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Exemestane: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Exemestane\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9119@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Vosilasarm: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Vosilasarm\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/vosilasarm#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/vosilasarm#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195227-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07195227)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With B
 reast Cancer\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07195227
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195227-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07195227)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Efficacy and Safety of Camizestrant Plus Ribociclib in Pat
 ients With Breast Cancer\nEstimated primary completion: February 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/camizestrant#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07195227
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466303-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07466303)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Serplu
 limab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Tripl
 e-Negative Breast Cancer\nEstimated primary completion: 1 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746
 6303
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383818-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07383818)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/
 HER2-low Breast Cancer (NEOTORCH-BREAST 08)\nEstimated primary completion:
  1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07383818
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205822-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07205822)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Dato-DXd in Inoperable or Metastatic Hormone Re
 ceptor-positive\, HER2 IHC 0 Breast Cancer\nEstimated primary completion: 
 2 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dato
 potamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07205822
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612891-9101@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280204
DTEND;VALUE=DATE:20280205
SUMMARY:INV-6452: Phase 1/2 readout est. (NCT07612891)
DESCRIPTION:INV-6452\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics\, and
  Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone
  Receptor Positive\, Human Epidermal Growth Factor Receptor 2 Negative (HR
 +/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic 
 Solid Tumor\nEstimated primary completion: 4 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/inv-6452#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07612891
URL:https://assetmemo.bio/drug/inv-6452#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914309-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07914309)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Dexamethasone 
 De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast
  Cancer\nEstimated primary completion: 8 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07914309
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05760612-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Neratinib: Phase 3 readout est. (NCT05760612)
DESCRIPTION:Neratinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Adju
 vant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epiderm
 al Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trast
 uzumab Plus Pertuzumab\nEstimated primary completion: 16 February 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05760612
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Study of AMXT 1501 and DFMO in Combination With Standard Therapie
 s in Advanced Solid Tumors\nEstimated primary completion: 28 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07287917
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Capivasertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Study of AMXT 1501 and DFMO in Combination With Standard Therapies
  in Advanced Solid Tumors\nEstimated primary completion: 28 February 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07287917
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AMXT 1501 and DFMO in Combination With Standard
  Therapies in Advanced Solid Tumors\nEstimated primary completion: 28 Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 287917
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06472583-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06472583)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Preoperative Immunotherapy Combined With Stereotactic Radiation The
 rapy Boost in the Treatment of HER2-negative Breast Cancer\nEstimated prim
 ary completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06472583
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Clin
 ical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07111832
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-2272@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Utidelone: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Pat
 ients With HER-2 Negative Advanced Breast Cancer\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/u
 tidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07684456
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in 
 Patients With HER-2 Negative Advanced Breast Cancer\nEstimated primary com
 pletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07684456
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904964-2454@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05904964)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Disitamab Vedotin (RC48) in Hormone Receptor Positive\, HER2-lo
 w Metastatic Breast Cancer (the Rosy Trial)\nEstimated primary completion:
  1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disita
 mab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05904964
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471776-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280311
DTEND;VALUE=DATE:20280312
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07471776)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study on Using TROP2-PET and 18F-FDG PET to Predict the Ef
 ficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer\nEstimated pr
 imary completion: 11 March 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07471776
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471776-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280311
DTEND;VALUE=DATE:20280312
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07471776)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study on Using TROP2-PET and 18F-FDG PET to Predict the E
 fficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer\nEstimated p
 rimary completion: 11 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07471776
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471776-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280311
DTEND;VALUE=DATE:20280312
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07471776)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study on Using TROP2-PET and 18F-FDG PET to Predict the Eff
 icacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer\nEstimated pri
 mary completion: 11 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07471776
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876714-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT06876714)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: ShortStop-HER2: 1
 2 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ B
 reast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plu
 s Trastuzumab\nEstimated primary completion: 13 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06876714
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441512-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07441512)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Phase
  II\, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib i
 n Combination With Eribulin in Pretreated Advanced Triple-negative Breast 
 Cancer Harboring a PIK3CA Mutation\nEstimated primary completion: 15 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0744151
 2
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441512-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07441512)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: A Phase II
 \, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in C
 ombination With Eribulin in Pretreated Advanced Triple-negative Breast Can
 cer Harboring a PIK3CA Mutation\nEstimated primary completion: 15 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 41512
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045311-2239@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280322
DTEND;VALUE=DATE:20280323
SUMMARY:JS207: Phase 2 readout est. (NCT07045311)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: JS207 Combination Ther
 apy in Triple-negative Breast Cancer\nEstimated primary completion: 22 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045311
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03412877-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280323
DTEND;VALUE=DATE:20280324
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03412877)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 dministration of Autologous T-Cells Genetically Engineered to Express T-Ce
 ll Receptors Reactive Against Neoantigens in People With Metastatic Cancer
 \nEstimated primary completion: 23 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03412877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795424-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07795424)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Cul
 merciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Th
 erapy for HR+/HER2+ Breast Cancer\nEstimated primary completion: 30 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07795424
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788197-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06788197)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of SHR-A1811 and Fulvestrant\, With or Without H
 S-10352\, in Locally Advanced or Metastatic Breast Cancer Patients\nEstima
 ted primary completion: 31 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06788197
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788197-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06788197)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SHR-A1811 and Fulvestrant\, With or Without HS
 -10352\, in Locally Advanced or Metastatic Breast Cancer Patients\nEstimat
 ed primary completion: 31 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06788197
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06184750-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06184750)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Finding
  the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal
  Women\, RENAISSANCE Trial\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0618475
 0
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860529-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06860529)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Serplulimab Combi
 ned With Chemotherapy for Early-stage HR+/HER2- Breast Cancer\nEstimated p
 rimary completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/epirubicin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06860529
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05840211-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05840211)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Sacituzumab Govitecan Versus Treatment of Physicia
 n's Choice in Patients With Hormone Receptor-positive/Human Epidermal Grow
 th Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Hav
 e Received Endocrine Therapy\nEstimated primary completion: April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05840
 211
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05128734-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Olaparib: Phase 2 readout est. (NCT05128734)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Temozolomide Monoth
 erapy or in Combination With Olaparib in Patients With Triple Negative Bre
 ast Cancer (TNBC)\nEstimated primary completion: 1 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05128734
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06065748)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Evaluate Efficacy and Safety of Giredestrant Co
 mpared With Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With E
 R-Positive\, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant En
 docrine Therapy (pionERA Breast Cancer)\nEstimated primary completion: 20 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemacicl
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6065748
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With 
 Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive\,
  HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Ther
 apy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06065748)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study to Evaluate Efficacy and Safety of Giredestrant Com
 pared With Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER
 -Positive\, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant End
 ocrine Therapy (pionERA Breast Cancer)\nEstimated primary completion: 20 A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbocicli
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 065748
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9126@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Giredestrant: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Giredestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared Wit
 h Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive
 \, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Th
 erapy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-2201@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Zanidatamab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A 
 Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Ea
 ch in Combination With Physician's Choice Chemotherapy\, for the Treatment
  of Participants With Metastatic HER2-positive Breast Cancer\nEstimated pr
 imary completion: 28 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377643-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07377643)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: IBI
 354 With or Without Pertuzumab Versus Taxane\, Trastuzumab and Pertuzumab 
 in HER2-positive Metastatic Breast Cancer\nEstimated primary completion: 2
 8 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07377643
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Eribulin mesylate: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Eribulin mesylate\, phase 3\, Breast Cancer.\nStudy: A Study Co
 mparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Each in Co
 mbination With Physician's Choice Chemotherapy\, for the Treatment of Part
 icipants With Metastatic HER2-positive Breast Cancer\nEstimated primary co
 mpletion: 28 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/eribulin-mesylate#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982521-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06982521)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + 
 Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant 
 HR+/HER2- Breast Cancer\nEstimated primary completion: 30 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06982521
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982521-9083@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Zovegalisib: Phase 3 readout est. (NCT06982521)
DESCRIPTION:Zovegalisib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant
  as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- B
 reast Cancer\nEstimated primary completion: 30 April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zovegalisib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06982521
URL:https://assetmemo.bio/drug/zovegalisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Phase Ib/II Study to Evaluate Multiple Combination The
 rapies of FWD1802 in Patients With ER+/HER2- BC\nEstimated primary complet
 ion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abem
 aciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07002177
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FW
 D1802 in Patients With ER+/HER2- BC\nEstimated primary completion: 1 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07002177
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FW
 D1802 in Patients With ER+/HER2- BC\nEstimated primary completion: 1 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07002177
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Phase Ib/II Study to Evaluate Multiple Combination Ther
 apies of FWD1802 in Patients With ER+/HER2- BC\nEstimated primary completi
 on: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07002177
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-9147@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:FWD1802: Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:FWD1802\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD18
 02 in Patients With ER+/HER2- BC\nEstimated primary completion: 1 May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/fwd1802#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07002177
URL:https://assetmemo.bio/drug/fwd1802#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05892068-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05892068)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: A Study of Tucatin
 ib Given Before Surgery to People With HER2+ Cancers That Have Spread to t
 he Brain\nEstimated primary completion: 9 May 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05892068
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905313-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07905313)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Study
  of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery i
 n Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis
  of Brain Metastases (HERBRAIN)\nEstimated primary completion: 15 May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07905313
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04348747-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04348747)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Dendritic Cell
  Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain M
 etastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer\nEstim
 ated primary completion: 15 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04348747
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616427-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280520
DTEND;VALUE=DATE:20280521
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07616427)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Fovinaciclib Plus
  Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadju
 vant Strategy for HR-Positive/HER2-Positive Early Breast Cancer\nEstimated
  primary completion: 20 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07616427
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949695-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07949695)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-P
 ositive HER2-Low Breast Cancer\nEstimated primary completion: 31 May 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 949695
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05891093)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Effic
 acy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for 
 HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)\nEstimated primar
 y completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05891093
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05891093)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Efficac
 y and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR
 +/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)\nEstimated primary 
 completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05891093
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Exemestane: Phase 3 readout est. (NCT05891093)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Efficacy and Safe
 ty of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SN
 F3-subtype Early Breast Cancer (BCTOP-L-A01)\nEstimated primary completion
 : 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemes
 tane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05891093
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926920-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06926920)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: A St
 udy of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in 
 Participants With Advanced Triple-Negative Breast Cancer\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06926920
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857226-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07857226)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trastuzumab/Pertu
 zumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07857226
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857226-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07857226)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Trast
 uzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Bre
 ast Cancer\nEstimated primary completion: June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07857226
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618923-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07618923)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer\nEstim
 ated primary completion: June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07618923
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441890-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06441890)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: BRE-10: Bioma
 rker Optimization of Neoadjuvant Therapy in Breast Cancer\nEstimated prima
 ry completion: June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06441890
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263543-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06263543)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA L
 OW MBC\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06263543
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497386-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07497386)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Trial of Trastuzumab Rezetecan in Unresectable Locally R
 ecurrent/Metastatic Breast Cancer\nEstimated primary completion: June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07497386
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441890-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06441890)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: BRE
 -10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer\nEstim
 ated primary completion: June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06441890
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06105684-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06105684)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase II Single Arm Trial of Low Dose Capecitabine in Patients With 
 Advanced Breast Cancer\nEstimated primary completion: June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06105684
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497386-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07497386)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial of Trastuzumab Rezetecan in Unresectable Locally Re
 current/Metastatic Breast Cancer\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 497386
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04565054-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04565054)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Adjuv
 ant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic Hi
 gh Risk\, HR+/HER2- EBC\nEstimated primary completion: June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04565054
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198724-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07198724)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trast
 uzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistan
 t HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer\nEstimated primar
 y completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07198724
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198724-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT07198724)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deru
 xtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-
 low or HER2-ultralow Metastatic Breast Cancer\nEstimated primary completio
 n: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elace
 strant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07198724
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04986579-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04986579)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Scalp Cooling in MBC\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-gov
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04986579
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04986579-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04986579)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Scalp Cooling in MBC\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04986579
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04986579-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT04986579)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Scalp Cooling in MBC\nEstimated primary completion: 1 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04986
 579
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805135-9029@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07805135)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients 
 With Advanced Breast Cancer\nEstimated primary completion: 1 June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07805135
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296798-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05296798)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: A Study to Evalua
 te the Efficacy and Safety of Giredestrant in Combination With Phesgo (Per
 tuzumab\, Trastuzumab\, and Hyaluronidase-zzxf) Versus Phesgo in Participa
 nts With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Can
 cer)\nEstimated primary completion: 15 June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05296798
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810088-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280628
DTEND;VALUE=DATE:20280629
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07810088)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the 
 First-line Treatment for HR+/HER2- Advanced Breast Cancer\nEstimated prima
 ry completion: 28 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07810088
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05708235-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05708235)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A PoC Study to Evaluate Treatments' Efficacy by Monitoring
  MRD Using ctDNA in HR-positive/HER2-negative EBC Population\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05708235
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05708235-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT05708235)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A PoC Study to Evaluate Treatments' Efficacy by Monitoring M
 RD Using ctDNA in HR-positive/HER2-negative EBC Population\nEstimated prim
 ary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05708235
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02942355-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Anastrozole: Phase 2 readout est. (NCT02942355)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Brea
 st Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02942355
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02942355-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02942355)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Trial of Anastrozole and Palbociclib in Metastatic HER2-Neg
 ative Breast Cancer\nEstimated primary completion: 30 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02942355
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05708235-9126@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Giredestrant: Phase 2 readout est. (NCT05708235)
DESCRIPTION:Giredestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using
  ctDNA in HR-positive/HER2-negative EBC Population\nEstimated primary comp
 letion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /giredestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05708235
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05485766-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05485766)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Novel Neoadjuv
 ant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Br
 east Cancer\nEstimated primary completion: 30 June 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05485766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05741164-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05741164)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Propranolol an
 d Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With 
 Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative
  Breast Cancer\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05741164
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05485766-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olaparib: Phase 2 readout est. (NCT05485766)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Novel Neoadjuvant a
 nd Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast 
 Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05485766
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530057-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT05530057)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Eribulin With or Without Trastuzumab-biosimilar in Patients Wit
 h HER2-overexpressed Recurrent or Stage IV Breast Cancer\nEstimated primar
 y completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05530057
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07666555-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07666555)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Clinical Study of the Efficacy and Safety of Cu
 lmerciclib Rechallenge in HR-positive\, HER2-negative Breast Cancer Patien
 ts With Resistance to First-line Endocrine Therapy.\nEstimated primary com
 pletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07666555
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07666555-9077@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07666555)
DESCRIPTION:Culmerciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib
  Rechallenge in HR-positive\, HER2-negative Breast Cancer Patients With Re
 sistance to First-line Endocrine Therapy.\nEstimated primary completion: 3
 0 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/culmerci
 clib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07666555
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037199-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07037199)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Efficacy and Safety of Trastuzumab Rezetecan Followed by CD
 K4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced B
 reast Cancer\nEstimated primary completion: 30 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07037199
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057427-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07057427)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Breast Cancer.\nStudy: Efficacy of N
 ab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast 
 Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07057427
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057427-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07057427)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Efficacy of Nab-P
 HP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Canc
 er\nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07057427
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797218-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07797218)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Neoadjuvant Pyrot
 inib-to-pertuzumab in HER2+ eBC\nEstimated primary completion: 30 June 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07797218
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806630-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07806630)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: SHORTened Duration of TAMoxifen\nEstimated primary completio
 n: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxif
 en-soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07806630
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382299-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382299)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Pa
 tients With Previously Untreated Locally Advanced Inoperable or Metastatic
  Triple-Negative Breast Cancer\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0538
 2299
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011654-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT07011654)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: Stud
 y of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Tripl
 e-negative Breast Cancer (TNBC)\nEstimated primary completion: 1 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7011654
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06062498)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Pati
 ents With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer\nE
 stimated primary completion: 1 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06062498)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ER
 positive/HER2-negative Advanced or Metastatic Breast Cancer\nEstimated pri
 mary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ribociclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06062498)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patie
 nts With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer\nEs
 timated primary completion: 1 July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06062498)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With E
 Rpositive/HER2-negative Advanced or Metastatic Breast Cancer\nEstimated pr
 imary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752550-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07752550)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Retlirafusp A
 lfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast C
 ancer\nEstimated primary completion: 30 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07752550
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019337-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07019337)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Oral
  Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-posit
 ive Metastatic Breast Cancer\nEstimated primary completion: 31 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07019337
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112053-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07112053)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy 
 or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive\
 , HER2 Negative Breast Cancer\nEstimated primary completion: 31 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07112053
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112053-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07112053)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemoth
 erapy for the Treatment of Metastatic Hormone Receptor Positive\, HER2 Neg
 ative Breast Cancer\nEstimated primary completion: 31 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07112053
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: ORION-1: Study of AVZO-023 as a Single Agent and in Comb
 ination With AVZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06998407
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With 
 AVZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\nEstimated pr
 imary completion: August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06998407
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9111@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:AVZO-021: Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:AVZO-021\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With A
 VZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\nEstimated pri
 mary completion: August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/avzo-021#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06998407
URL:https://assetmemo.bio/drug/avzo-021#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9112@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:AVZO-023: Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:AVZO-023\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With A
 VZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\nEstimated pri
 mary completion: August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/avzo-023#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06998407
URL:https://assetmemo.bio/drug/avzo-023#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449222-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT06449222)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Safety and Preliminary Effectiveness of BNT327\, an Investigati
 onal Therapy for Breast Cancer\, When Given in Combination With Chemothera
 py\nEstimated primary completion: August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06449222
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458113-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07458113)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: Sac-
 TMT for Active TNBC Brain Metastases\nEstimated primary completion: August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-ti
 rumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07458113
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05973864-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05973864)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Capecitabine P
 lus Pembrolizumab in Patients With Triple Negative Breast Cancer After Che
 mo-immunotherapy and Surgery\nEstimated primary completion: August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05973864
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371208-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07371208)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: Mult
 icenter\, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in 
 Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Brea
 st Cancer\nEstimated primary completion: August 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07371208
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900516-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Everolimus: Phase 2 readout est. (NCT07900516)
DESCRIPTION:Everolimus\, phase 2\, Breast Cancer.\nStudy: A Prospective\, P
 hase II\, Exploratory Study Protocol of a Chemotherapy Sensitivity-based C
 ulmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breas
 t Cancer.\nEstimated primary completion: 1 August 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07900516
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900516-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07900516)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: A Prospective\, P
 hase II\, Exploratory Study Protocol of a Chemotherapy Sensitivity-based C
 ulmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breas
 t Cancer.\nEstimated primary completion: 1 August 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07900516
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregio
 nal Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast Ca
 ncer\nEstimated primary completion: 15 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregi
 onal Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast C
 ancer\nEstimated primary completion: 15 August 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05467891)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Ribociclib And Endocrine Treatment of Physician's Choice f
 or Locoregional Recurrent\, Resected Hormone Receptor Positive HER2 Negati
 ve Breast Cancer\nEstimated primary completion: 15 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Letrozole: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregion
 al Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast Can
 cer\nEstimated primary completion: 15 August 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Exemestane: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregio
 nal Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast Ca
 ncer\nEstimated primary completion: 15 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132242-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07132242)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: SHR-
 A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive
  Breast Cancer\nEstimated primary completion: 30 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07132242
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132242-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07132242)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic H
 ER2 Positive Breast Cancer\nEstimated primary completion: 30 August 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 32242
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100106-9089@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Vustanaciclib: Phase 1/2 readout est. (NCT07100106)
DESCRIPTION:Vustanaciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: A Study to Evaluate the Effect of GDC-4198 Alone and in Combinati
 on With Giredestrant Versus Abemaciclib and Giredestrant in Participants W
 ith Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+)\, Huma
 n Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer\nEstimat
 ed primary completion: 31 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vustanaciclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07100106
URL:https://assetmemo.bio/drug/vustanaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100106-9126@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Giredestrant: Phase 1/2 readout est. (NCT07100106)
DESCRIPTION:Giredestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Evaluate the Effect of GDC-4198 Alone and in Combinatio
 n With Giredestrant Versus Abemaciclib and Giredestrant in Participants Wi
 th Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+)\, Human
  Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/giredestrant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07100106
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06086704-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06086704)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of 18F-FFNP Breast PET/MRI\nEstimated primary completion: 31 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 086704
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680921-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Everolimus: Phase 3 readout est. (NCT06680921)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician
 's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)\nEst
 imated primary completion: 31 August 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06680921
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393321-9073@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:NTQ1062: Phase 3 readout est. (NCT07393321)
DESCRIPTION:NTQ1062\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for
  the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ntq1062#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07393321
URL:https://assetmemo.bio/drug/ntq1062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377852-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06377852)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study\nEstimated primary c
 ompletion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06377852
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377852-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06377852)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06377852
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861932-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07861932)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Phase 1/2a Study of K-1728 in Advanced Solid Tumors\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07861932
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861932-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT07861932)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Phase 1/2a Study of K-1728 in Advanced Solid Tumors\nEs
 timated primary completion: September 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07861932
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06361940-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06361940)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Molecul
 ar Analyses to Predict Pathways of Endocrine Resistance Following Short Te
 rm Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Posit
 ive HER2-negative Breast Cancer\nEstimated primary completion: September 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltam
 ox#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6361940
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947823-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07947823)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: ASTAR:
  Sacituzumab Govitecan For Breast Cancer\nEstimated primary completion: 1 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacit
 uzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07947823
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016399-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07016399)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Da
 rolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA
 \, AR+\, TNBC\nEstimated primary completion: 1 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07016399
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016399-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07016399)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Darol
 utamide Alone or in Combination With Standard Therapy for Stage II-IIIA\, 
 AR+\, TNBC\nEstimated primary completion: 1 September 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07016399
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726148-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of ECI830 Single Agent or in Combination in Patients With Adva
 nced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tum
 ors\nEstimated primary completion: 25 September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726148-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of ECI830 Single Agent or in Combination in Patien
 ts With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanc
 ed Solid Tumors\nEstimated primary completion: 25 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726148-9116@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:ECI830: Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:ECI830\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Study of ECI830 Single Agent or in Combination in Patients With Advanced
  HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors\
 nEstimated primary completion: 25 September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/eci830#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/eci830#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619066-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07619066)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Study of Zongertinib Plus Fulvestrant in Partic
 ipants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER
 2 Mutations.\nEstimated primary completion: 28 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07619066
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177950-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT07177950)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, HER2-Positive Breast Cancer
 .\nStudy: A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positiv
 e Breast Cancer With Brain Metastases\nEstimated primary completion: 30 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07177950
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407920-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07407920)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Ph2 Study for 
 Optimization of Adjunct Systemic Therapy in HER2+ Patients\, MolecularPCR 
 Trial\nEstimated primary completion: 30 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07407920
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182721-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07182721)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: SKB2
 64 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Prog
 ressing After T-DXd Treatment\nEstimated primary completion: 30 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07182721
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407920-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07407920)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Ph2 Study for Opt
 imization of Adjunct Systemic Therapy in HER2+ Patients\, MolecularPCR Tri
 al\nEstimated primary completion: 30 September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07407920
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817082-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07817082)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Bre
 ast Cancer\nEstimated primary completion: 30 September 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07817082
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294534-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT07294534)
DESCRIPTION:Pertuzumab\, phase 2/3\, Breast Cancer.\nStudy: A Phase II/III 
 Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination 
 With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresa
 t Cancer\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07294534
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669610-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07669610)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: An Ope
 n-Label\, Randomized Phase III Study of Trastuzumab Rezetecan With or With
 out Bevacizumab in First to Third Line BLIS Subtype TNBC\nEstimated primar
 y completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07669610
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760844-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07760844)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: An Ope
 n-Label\, Randomized Phase III Study of Trastuzumab Rezetecan With or With
 out Everolimus in First to Third Line LAR Subtype TNBC\nEstimated primary 
 completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07760844
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590857-9190@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 1/2 readout est. (NCT06590857
 )
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 1/2\, HR+/HER2- Metastat
 ic Breast Cancer.\nStudy: Trial of 225Ac-DOTATATE (RYZ101) in Subjects Wit
 h ER+\, HER2-negative Unresectable or Metastatic Breast Cancer Expressing 
 SSTRs.\nEstimated primary completion: October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06590857
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04230109-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04230109)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Sacituzumab Go
 vitecan In TNBC\nEstimated primary completion: October 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04230109
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04230109-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04230109)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Sacitu
 zumab Govitecan In TNBC\nEstimated primary completion: October 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04230109
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766018-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07766018)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Me
 tastatic Breast Cancer\nEstimated primary completion: October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07766018
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317778-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07317778)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Chemot
 herapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR
 +/HER2 Low Early Stage Breast Cancer\nEstimated primary completion: 15 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07317778
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840443-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281026
DTEND;VALUE=DATE:20281027
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07840443)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase II Study of CAmizestrant in Resectable Endometrial A
 denocarcinoma\nEstimated primary completion: 26 October 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/camizestrant#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07840443
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836257-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07836257)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: A Pha
 se II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Posit
 ive Advanced Breast Cancer After Progression on T-DXd\nEstimated primary c
 ompletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07836257
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368998-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07368998)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: To Study the Effect of Inavolisib in Combination With Fulves
 trant in Participants With Breast Cancer\nEstimated primary completion: 31
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavol
 isib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07368998
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368998-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07368998)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: To Study the Effect of Inavolisib in Combination With Fulv
 estrant in Participants With Breast Cancer\nEstimated primary completion: 
 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulv
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07368998
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610720-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07610720)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Dalpiciclib\, Ant
 i-HER2 Therapy\, and Endocrine Therapy for Hormone-Receptor-Positive\, HER
 2-Positive Metastatic Breast Cancer\nEstimated primary completion: 1 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 0720
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04893109-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04893109)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: ATEMPT 2.0: Adjuvant T-DM1 vs TH\nEstimated primary completion: 1 
 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-emtansine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04893109
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235176-9171@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:QLS1304: Phase 1/2 readout est. (NCT07235176)
DESCRIPTION:QLS1304\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy i
 n the Treatment of ER+/HER2- Breast Cancer Patients\nEstimated primary com
 pletion: 2 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/qls1304#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07235176
URL:https://assetmemo.bio/drug/qls1304#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340619-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281118
DTEND;VALUE=DATE:20281119
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07340619)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Clinical Trial Evaluating the Biological Activity of a New
  Drug Identified as Prifetrastat (PF-07248144)\, Combined With Fulvestrant
  for the Treatment of Patients With Hormone Receptor Positive (HR+) and HE
 R2 Negative (HER2-) Breast Cancer Extended to Other Organs.\nEstimated pri
 mary completion: 18 November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07340619
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340619-9082@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281118
DTEND;VALUE=DATE:20281119
SUMMARY:Prifetrastat: Phase 2 readout est. (NCT07340619)
DESCRIPTION:Prifetrastat\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Clinical Trial Evaluating the Biological Activity of a New Drug Iden
 tified as Prifetrastat (PF-07248144)\, Combined With Fulvestrant for the T
 reatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negativ
 e (HER2-) Breast Cancer Extended to Other Organs.\nEstimated primary compl
 etion: 18 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/prifetrastat#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07340619
URL:https://assetmemo.bio/drug/prifetrastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvan
 t/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negat
 ive Breast Cancer\nEstimated primary completion: 20 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Olaparib: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Olaparib\, phase 3\, Breast Cancer.\nStudy: A Phase III Randomi
 sed Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Tre
 atment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Can
 cer\nEstimated primary completion: 20 November 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Epirubicin: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: A Phase III Rando
 mised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant T
 reatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast C
 ancer\nEstimated primary completion: 20 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292207-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07292207)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Abema
 ciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in
  HR+/HER2- Early Breast Cancer\nEstimated primary completion: 30 November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729220
 7
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06434064-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06434064)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Tamoxif
 en and Pegylated Liposomal Doxorubicin for the Treatment of Patients With 
 Metastatic or Inoperable\, Locally Advanced Triple Negative Breast Cancer\
 nEstimated primary completion: 30 November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06434064
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784036-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07784036)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER
 2- Advanced Breast Cancer\nEstimated primary completion: 30 November 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07784036
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785856-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07785856)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Stu
 dy of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor 
 in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Brea
 st Cancer\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07785856
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2708@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 1/2\, Non-Small Cell Lung
  Cancer.\nStudy: Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Adv
 anced Solid Tumors (GCT1184-01/ PRO1184-001)\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rina
 tabart-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of HRS-6208 in Combination With HRS-8080\, or Fu
 lvestrant\, or Letrozole\, With or Without HRS-6209 in Patients With Advan
 ced Unresectable or Metastatic Breast Cancer\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulv
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07389733
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, o
 r Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresecta
 ble or Metastatic Breast Cancer\nEstimated primary completion: December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9146@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SHR-6209: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:SHR-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, or
  Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresectab
 le or Metastatic Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/shr-6209#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9181@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-6209: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:HRS-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, or
  Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresectab
 le or Metastatic Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-6209#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-11068@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-8080: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:HRS-8080\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, or
  Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresectab
 le or Metastatic Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-11084@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-6208: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:HRS-6208\, phase 1/2\, Breast Cancer.\nStudy: A Study of HRS-62
 08 in Combination With HRS-8080\, or Fulvestrant\, or Letrozole\, With or 
 Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Brea
 st Cancer\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/hrs-6208#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/hrs-6208#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618390-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07618390)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Phase ll\, Interventional\, Single-arm Study Evaluating the Efficacy
  and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patie
 nts With PIK3CA-mutant\, HR-positive\, HER2-negative Locally Advanced or M
 etastatic Breast Cancer.\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07618390
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618390-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07618390)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Phase ll\, Interventional\, Single-arm Study Evaluating th
 e Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chi
 nese Patients With PIK3CA-mutant\, HR-positive\, HER2-negative Locally Adv
 anced or Metastatic Breast Cancer.\nEstimated primary completion: December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761839
 0
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618390-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07618390)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase ll\, Interventional\, Single-arm Study Evaluating 
 the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in C
 hinese Patients With PIK3CA-mutant\, HR-positive\, HER2-negative Locally A
 dvanced or Metastatic Breast Cancer.\nEstimated primary completion: Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 8390
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395336-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07395336)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Met
 astatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07395336
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395336-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07395336)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Meta
 static Breast Cancer and [18F] FES-avid Lesions (COMBINE)\nEstimated prima
 ry completion: December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07395336
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891833-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT06891833)
DESCRIPTION:Pertuzumab\, phase 2/3\, HER2-Positive Breast Cancer.\nStudy: A
  Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplat
 in + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Bre
 ast Cancer\nEstimated primary completion: December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06891833
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288777-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Emtansine: Phase 2/3 readout est. (NCT05288777)
DESCRIPTION:Trastuzumab Emtansine\, phase 2/3\, Breast Cancer.\nStudy: Adju
 vant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05288777
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891833-2282@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 2/3 readout est. (NCT06891833)
DESCRIPTION:Trastuzumab brengitecan\, phase 2/3\, HER2-Positive Breast Canc
 er.\nStudy: A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxe
 l + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2
 -Positive Breast Cancer\nEstimated primary completion: December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06891
 833
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648914-2044@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07648914)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Comparing BL-B01D1 With Chemotherapy of Physician
 's Choice in Patients With Unresectable Locally Advanced\, Recurrent\, or 
 Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therap
 y(PANKU-Breast03)\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07648914
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085767-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07085767)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Palazestrant in Combination With Ribociclib for the First-line Treatme
 nt of ER+/HER2- Advanced Breast Cancer\nEstimated primary completion: Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 85767
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085767-2666@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Palazestrant: Phase 3 readout est. (NCT07085767)
DESCRIPTION:Palazestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Palazestrant in Combination With Ribociclib for the First-line Treat
 ment of ER+/HER2- Advanced Breast Cancer\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palazest
 rant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07085767
URL:https://assetmemo.bio/drug/palazestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354022-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07354022)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalp
 iciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to
  Adjuvant Endocrine Therapy.\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07354022
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354022-11068@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07354022)
DESCRIPTION:HRS-8080\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpici
 clib in Patients With Advanced or Metastatic Breast Cancer Resistant to Ad
 juvant Endocrine Therapy.\nEstimated primary completion: December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07354022
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193394-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Tucatinib: Phase 2 readout est. (NCT07193394)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Tucatinib and Tras
 tuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer\nEs
 timated primary completion: 7 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07193394
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04646759-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT04646759)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+
 /HER2+ Metastatic Breast Cancer\nEstimated primary completion: 14 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046467
 59
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634601-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281218
DTEND;VALUE=DATE:20281219
SUMMARY:Everolimus: Phase 2 readout est. (NCT07634601)
DESCRIPTION:Everolimus\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant With Everolimus for the Treatment of Recurrent Advanced or
  Metastatic ER-Positive Endometrial Cancer\nEstimated primary completion: 
 18 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eve
 rolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07634601
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634601-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281218
DTEND;VALUE=DATE:20281219
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07634601)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant With Everolimus for the Treatment of Recurrent Advanced o
 r Metastatic ER-Positive Endometrial Cancer\nEstimated primary completion:
  18 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/el
 acestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07634601
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405801-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07405801)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Phase II Study Evaluating the Efficacy and Safety of Inavo
 lisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus
  Fulvestrant in Participants With Advanced Breast Cancer\nEstimated primar
 y completion: 19 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07405801
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410676-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07410676)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab
  in Advanced Solid Tumors\nEstimated primary completion: 21 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410676
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460752-8458@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Goserelin: Phase 2 readout est. (NCT07460752)
DESCRIPTION:Goserelin\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian 
 Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hor
 mone Receptor Positive Breast Cancer Patients\nEstimated primary completio
 n: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 goserelin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07460752
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01174121-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT01174121)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients Wit
 h Metastatic Cancer\nEstimated primary completion: 27 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT01174121
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035836-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT05035836)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: A Phase
  2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Pati
 ents With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)\nEstima
 ted primary completion: 29 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05035836
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109726-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07109726)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Phase 1/2 Trial of TER-2013 in Patients With Solid Tum
 ors Harboring AKT/PI3K/PTEN Pathway Alterations\nEstimated primary complet
 ion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07109726
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05769010-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05769010)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of SHR-A1811 in HER2-expression Advanced Breast Cance
 r With Brain Metastases\nEstimated primary completion: 30 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576
 9010
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615751-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07615751)
DESCRIPTION:Pyrotinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Pyro
 tinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docet
 axel in Advanced HER2-Positive Breast Cancer\nEstimated primary completion
 : 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 yrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07615751
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03449238-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03449238)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Bra
 in Metastases In Breast Cancer Patients\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03449238
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05575804-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05575804)
DESCRIPTION:Pyrotinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: GQ
 1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic B
 reast Cancer\nEstimated primary completion: 31 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05575804
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560475-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07560475)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Exploratory Study of SHR-A1811 Via Different Administration
  Routes in Patients\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07560475
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant T
 rastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel\, Carboplatin\, Tra
 stuzumab\, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER
 2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breas
 t Cancer\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06201234-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06201234)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inh
 ibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06201234
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524584-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05524584)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Anastrazole\, Fulvestrant & Abemaciclib for HR+HER2- Metas
 tatic Breast Cancer\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05524584
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750484-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06750484)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trial of Trastuzumab Deruxtecan in Previously Treated HER2
 \nEstimated primary completion: 31 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06750484
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816655-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05816655)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Ful
 vestrant + Letrozole + Ribociclib in Hormone Receptor Positive\, HER2 Nega
 tive Metastatic Breast Cancer\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05816655
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Trast
 uzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel\, Carboplatin\, Trastuz
 umab\, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Ta
 rgeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Ca
 ncer\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524584-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05524584)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Anastrazole\, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breas
 t Cancer\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05524584
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524584-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05524584)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Anastrazole\, Fulvestrant & Abemaciclib for HR+HER2- Metas
 tatic Breast Cancer\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05524584
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816655-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05816655)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Comparison of Clinical Efficacy Between Letrozole + Riboci
 clib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive
 \, HER2 Negative Metastatic Breast Cancer\nEstimated primary completion: 3
 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulv
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05816655
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06201234-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06201234)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-
 inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer\nE
 stimated primary completion: 31 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06201234
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732491-9077@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07732491)
DESCRIPTION:Culmerciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Culmerciclib in HR+/HER2+ Advanced Breast Cancer\nEstimated primary 
 completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07732491
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel\, Carboplati
 n\, Trastuzumab\, and Pyrotinib After Suboptimal Response to Neoadjuvant D
 ual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Earl
 y Breast Cancer\nEstimated primary completion: 31 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382687-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07382687)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Famitinib Combined With SHR-A1811\, Versus SHR-A1811 for CD
 K4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subty
 pe\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07382687
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889688-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Eribulin mesylate: Phase 3 readout est. (NCT06889688)
DESCRIPTION:Eribulin mesylate\, phase 3\, Breast Cancer.\nStudy: Phase III 
 Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherap
 y in Advanced Triple-Negative Breast Cancer\nEstimated primary completion:
  31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/er
 ibulin-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06889688
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287098-9192@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07287098)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Recep
 tor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2
 -) Early Breast Cancer\nEstimated primary completion: January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07287098
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760637-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Letrozole: Phase 3 readout est. (NCT06760637)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-neg
 ative Breast Cancer Who Have Not Received Anticancer Treatment for Advance
 d/Metastatic Disease\nEstimated primary completion: 2 January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06760637
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760637-9131@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Atirmociclib: Phase 3 readout est. (NCT06760637)
DESCRIPTION:Atirmociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-
 negative Breast Cancer Who Have Not Received Anticancer Treatment for Adva
 nced/Metastatic Disease\nEstimated primary completion: 2 January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06760637
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Bea
 mion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and
  in Combination With Other Treatments to Test Whether it Helps People With
  Different Types of HER2+ Cancer That Has Spread\nEstimated primary comple
 tion: 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06324357
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Trastuzumab Emtansine: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Trastuzumab Emtansine\, phase 1/2\, Breast Cancer.\nStudy: Beam
 ion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and 
 in Combination With Other Treatments to Test Whether it Helps People With 
 Different Types of HER2+ Cancer That Has Spread\nEstimated primary complet
 ion: 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-emtansine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06324357
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610525-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07610525)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Blood and imag
 E-guided Optimization of Neoadjuvant Therapy in People With Early Stage Tr
 iple-negative Breast cancER - the BETTER Trial\nEstimated primary completi
 on: 15 January 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07610525
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417241-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07417241)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: SHR-
 A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Br
 east Cancer: A Randomized Study\nEstimated primary completion: 31 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07417241
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417241-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07417241)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+
  Advanced Breast Cancer: A Randomized Study\nEstimated primary completion:
  31 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07417241
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857486-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07857486)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Reduction of N
 eoadjuvant Treatment in Early Triple-Negative Breast Cancer\nEstimated pri
 mary completion: February 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07857486
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340658-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07340658)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compar
 ed With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in P
 ostmenopausal Women With HR-Positive\, HER2-Negative\, Inoperable Locally 
 Advanced or Metastatic Breast Cancer\nEstimated primary completion: Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07340
 658
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340658-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Letrozole: Phase 3 readout est. (NCT07340658)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compare
 d With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Po
 stmenopausal Women With HR-Positive\, HER2-Negative\, Inoperable Locally A
 dvanced or Metastatic Breast Cancer\nEstimated primary completion: Februar
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0734065
 8
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581795-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07581795)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Stu
 dy of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus
  Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positiv
 e Breast Cancer\nEstimated primary completion: 28 February 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07581795
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647328-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07647328)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-posi
 tive\, HER2-negative Advanced Breast Cancer\nEstimated primary completion:
  28 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07647328
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647328-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT07647328)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase IIIb Study to Evaluate Camizestrant Plus Ribocicli
 b in ER-positive\, HER2-negative Advanced Breast Cancer\nEstimated primary
  completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/camizestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07647328
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04569747-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290323
DTEND;VALUE=DATE:20290324
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04569747)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A S
 ingle Arm Phase II Study of ADjuvant Endocrine Therapy\, Pertuzumab\, and 
 Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive\,
  HER2-positive Breast Cancer\nEstimated primary completion: 23 March 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04569747
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06757634)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 3 Study of Gedatolisib as First-Line Treatment for P
 atients With HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA-
 2)\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06757634)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Phase 3 Study of Gedatolisib as First-Line Treatment for Pa
 tients With HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA-2
 )\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Letrozole: Phase 3 readout est. (NCT06757634)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With 
 HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)\nEstimated
  primary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9093@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Revtorpyk (Gedatolisib): Phase 3 readout est. (NCT06757634)
DESCRIPTION:Revtorpyk (Gedatolisib)\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Phase 3 Study of Gedatolisib as First-Line Treatment for 
 Patients With HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA
 -2)\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gedatolisib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/gedatolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787338-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07787338)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy fo
 r Stage II-III HER2-Positive Breast Cancer\nEstimated primary completion: 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07787338
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492641-2389@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:BGB-43395: Phase 3 readout est. (NCT07492641)
DESCRIPTION:BGB-43395\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients Wit
 h Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Pri
 or Treatment for Advanced or Metastatic Disease\nEstimated primary complet
 ion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bgb-
 43395#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492641
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492641-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Letrozole: Phase 3 readout est. (NCT07492641)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients Wit
 h Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Pri
 or Treatment for Advanced or Metastatic Disease\nEstimated primary complet
 ion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letr
 ozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492641
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410559-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07410559)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Neoad
 juvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 
 2 Weeks for ER-Positive HER2-Negative Breast Cancer\nEstimated primary com
 pletion: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07410559
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410559-9192@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07410559)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: Neoa
 djuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After
  2 Weeks for ER-Positive HER2-Negative Breast Cancer\nEstimated primary co
 mpletion: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/imlunestrant#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07410559
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406542-2211@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:CPO301: Phase 3 readout est. (NCT07406542)
DESCRIPTION:CPO301\, phase 3\, Breast Cancer.\nStudy: A Phase III Study of 
 SYS6010 Versus Chemotherapy in HER2-Negative\, EGFR-Positive Recurrent or 
 Metastatic Breast Cancer\nEstimated primary completion: 1 April 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07406542
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428018-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07428018)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Pragm
 atic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in
  HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib\nEstimate
 d primary completion: 30 April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07428018
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612215-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT07612215)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: E
 lacestrant in Advanced Triple Positive Breast Cancer\nEstimated primary co
 mpletion: May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 ertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07612215
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Sapanisertib and Serabelisib (PIKTOR) in Various Combina
 tions in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstima
 ted primary completion: May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07558733
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612215-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT07612215)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Elacestrant in Advanced Triple Positive Breast Cancer\nEstimated pr
 imary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/elacestrant#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07612215
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9074@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Serabelisib: Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Serabelisib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Pa
 tients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstimated primary
  completion: May 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/serabelisib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07558733
URL:https://assetmemo.bio/drug/serabelisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9075@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Sapanisertib: Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Sapanisertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in P
 atients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstimated primar
 y completion: May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sapanisertib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07558733
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174336-9063@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tersolisib: Phase 3 readout est. (NCT07174336)
DESCRIPTION:Tersolisib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treat
 ments in Participants With Advanced Breast Cancer With a Genetic Change (P
 IK3CA)\nEstimated primary completion: May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tersolisib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07174336
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527806-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07527806)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Optimization 
 of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer 
 Based on HER2-PET/CT Molecular Imaging\nEstimated primary completion: 1 Ma
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxe
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 527806
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527806-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07527806)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Opt
 imization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Brea
 st Cancer Based on HER2-PET/CT Molecular Imaging\nEstimated primary comple
 tion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/per
 tuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07527806
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06927180-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06927180)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: SHR-A1811 Plus Pe
 rtuzumab in the Neoadjuvant Treatment of HER2 Positive BC\nEstimated prima
 ry completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06927180
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06927180-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06927180)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: SHR-A1
 811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC\nEsti
 mated primary completion: 1 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06927180
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413939-11326@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Bizrolertinib: Phase 2/3 readout est. (NCT07413939)
DESCRIPTION:Bizrolertinib\, phase 2/3\, HER2-Positive Breast Cancer.\nStudy
 : RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitab
 ine in People With Locally Advanced or Metastatic Breast Cancer That is Hu
 man Epidermal Growth Factor Receptor 2 (HER2)-Positive\nEstimated primary 
 completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bizrolertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07413939
URL:https://assetmemo.bio/drug/bizrolertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Participants With Breast Cancer\nEstimated primar
 y completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04802759
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Com
 binations in Participants With Breast Cancer\nEstimated primary completion
 : 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/riboci
 clib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04802759
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Itovebi (Inavolisib): Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1/2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tre
 atment Combinations in Participants With Breast Cancer\nEstimated primary 
 completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/inavolisib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04802759
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Com
 binations in Participants With Breast Cancer\nEstimated primary completion
 : 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/everol
 imus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04802759
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tr
 eatment Combinations in Participants With Breast Cancer\nEstimated primary
  completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04802759
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-9099@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Samuraciclib: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Samuraciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Participants With Breast Cancer\nEstimated primary completi
 on: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/samu
 raciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04802759
URL:https://assetmemo.bio/drug/samuraciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07207070)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Randomised\, Open-label\, Multicentre Phase III Clinical
  Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpicic
 lib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients 
 With PIK3CA-mutated\, HR-positive\, HER2-negative Recurrent or Metastatic 
 Breast Cancer.\nEstimated primary completion: 31 May 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07207070)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Randomised\, Open-label\, Multicentre Phase III Clinical Study to E
 valuate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Ful
 vestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA
 -mutated\, HR-positive\, HER2-negative Recurrent or Metastatic Breast Canc
 er.\nEstimated primary completion: 31 May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9068@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:JS105: Phase 3 readout est. (NCT07207070)
DESCRIPTION:JS105\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy: A
  Randomised\, Open-label\, Multicentre Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestra
 nt Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutat
 ed\, HR-positive\, HER2-negative Recurrent or Metastatic Breast Cancer.\nE
 stimated primary completion: 31 May 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/js105#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/js105#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730125-9187@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:CRG-150: Phase 1/2 readout est. (NCT07730125)
DESCRIPTION:CRG-150\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/
 Refractory Malignancies\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/crg-150#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07730125
URL:https://assetmemo.bio/drug/crg-150#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06245889-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06245889)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: PET Dynamics t
 o Response-Adapted Neoadjuvant Therapy in TNBC\nEstimated primary completi
 on: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06245889
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06245889-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olaparib: Phase 2 readout est. (NCT06245889)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: PET Dynamics to Res
 ponse-Adapted Neoadjuvant Therapy in TNBC\nEstimated primary completion: J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062458
 89
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647263-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07647263)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tra
 stuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Ea
 rly Breast Cancer\nEstimated primary completion: June 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07647263
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647263-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07647263)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-
 Positive Early Breast Cancer\nEstimated primary completion: June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076472
 63
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291064-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06291064)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Trial Studying Ch
 emotherapy in Nigerian Women With Triple Negative Breast Cancer\nEstimated
  primary completion: June 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/epirubicin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06291064
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestrant 
 With or Without Palbociclib in Participants With Advanced Breast Cancer (A
 BC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestran
 t With or Without Palbociclib in Participants With Advanced Breast Cancer 
 (ABC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestrant
  With or Without Palbociclib in Participants With Advanced Breast Cancer (
 ABC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605728-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07605728)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Probiotics for Abemaciclib-Induced Abdominal Discomfort.\n
 Estimated primary completion: 30 June 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07605728
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Anastrozole: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Comparing Endocrine Therapy Combined With High-Dose Palbociclib and H
 ydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palboci
 clib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cance
 r\nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT07061717)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Comparing Endocrine Therapy Combined With High-Dose Palboci
 clib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Do
 se Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Br
 east Cancer\nEstimated primary completion: 1 July 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Letrozole: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hyd
 roxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbocicl
 ib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer\
 nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Exemestane: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hy
 droxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbocic
 lib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
 \nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: A Study of Disitam
 ab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated primary 
 completion: 28 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06157892
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391774-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07391774)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Testing Whether H
 ormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by
  Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage 
 Breast Cancer With Low Recurrence Risk\, The RxFINE-Low Trial\nEstimated p
 rimary completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07391774
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391774-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Exemestane: Phase 3 readout est. (NCT07391774)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Testing Whether H
 ormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by
  Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage 
 Breast Cancer With Low Recurrence Risk\, The RxFINE-Low Trial\nEstimated p
 rimary completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07391774
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827236-2448@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Trastuzumab pamirtecan: Phase 1/2 readout est. (NCT06827236)
DESCRIPTION:Trastuzumab pamirtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Clinical Study to Find the Optimal Dose of an Investig
 ational Treatment Called BNT323 When Used in Combination With Another Inve
 stigational Treatment\, BNT327\, and to Test if That Combination Treatment
  is Safe and Beneficial for Patients With Advanced Breast Cancer\nEstimate
 d primary completion: August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06827236
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152782-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Neratinib: Phase 2 readout est. (NCT07152782)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: T-DX
 d With or Without Neratinib for HER2 Positive Breast Cancer With Brain Met
 astasis\nEstimated primary completion: August 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07152782
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT06492616)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: A Study
  of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER
 +\,HER2-\, Early Breast Cancer With High Risk of Recurrence\nEstimated pri
 mary completion: August 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06492616
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Elacestrant: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: A Study of Elace
 strant Versus Standard Endocrine Therapy in Women and Men With ER+\,HER2-\
 , Early Breast Cancer With High Risk of Recurrence\nEstimated primary comp
 letion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06492616
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Exemestane: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: A Study of Elaces
 trant Versus Standard Endocrine Therapy in Women and Men With ER+\,HER2-\,
  Early Breast Cancer With High Risk of Recurrence\nEstimated primary compl
 etion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 xemestane#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06492616
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738341-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07738341)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: GB268 Monotherapy or Combination Therapy for Locally Advanced/Me
 tastatic Breast Cancer (Phase Ib/Ⅱ)\nEstimated primary completion: 1 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclita
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07738341
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738341-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07738341)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: GB268 Monotherapy or Combination Therapy for Locally Adv
 anced/Metastatic Breast Cancer (Phase Ib/Ⅱ)\nEstimated primary completio
 n: 1 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dat
 opotamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07738341
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738341-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07738341)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: GB268 Monotherapy or Combination Therapy for Locally Ad
 vanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)\nEstimated primary completi
 on: 1 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07738341
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539753-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07539753)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in
  HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases\nE
 stimated primary completion: 1 August 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07539753
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371585-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07371585)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer Wit
 h Proactive Toxicity Management\nEstimated primary completion: 1 August 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07371585
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371585-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07371585)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive 
 Toxicity Management\nEstimated primary completion: 1 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07371585
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumor
 s\nEstimated primary completion: 27 August 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumors
 \nEstimated primary completion: 27 August 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Letrozole: Phase 2 readout est. (NCT04606446)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of PF-07248144 in Advanced or Metastatic Solid Tumors\nEstimated 
 primary completion: 27 August 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9082@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Prifetrastat: Phase 2 readout est. (NCT04606446)
DESCRIPTION:Prifetrastat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of PF-07248144 in Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: 27 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/prifetrastat#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/prifetrastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9103@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Veppanu (Vepdegestrant): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumo
 rs\nEstimated primary completion: 27 August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vepdegestrant#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9131@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT04606446)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 27 August 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976944-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976944)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Pembrolizumab 
 + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer\nEstimated 
 primary completion: September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06976944
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081244-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06081244)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: NeoAdj. Therap
 y Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk\, 
 Triple-neg. EBC (ADAPT-TN-III)\nEstimated primary completion: September 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0608124
 4
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081244-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06081244)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: NeoAdj
 . Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low
 -risk\, Triple-neg. EBC (ADAPT-TN-III)\nEstimated primary completion: Sept
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzum
 ab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06081244
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164976-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT07164976)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer\nE
 stimated primary completion: 1 September 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07164976
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Ribociclib: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Phase IIIb Study 
 of Ribociclib + ET in Early Breast Cancer\nEstimated primary completion: 7
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05827081
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Exemestane: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Phase IIIb Study 
 of Ribociclib + ET in Early Breast Cancer\nEstimated primary completion: 7
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exem
 estane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05827081
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743190-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20290922
DTEND;VALUE=DATE:20290923
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07743190)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: A Phase II Stu
 dy of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant 
 Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Pat
 ients With High Tumor-Infiltrating Lymphocytes (TILs)\nEstimated primary c
 ompletion: 22 September 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07743190
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151586-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07151586)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Testin
 g Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) C
 ombinations Prescribed in an Alterning Pattern to Patients With Metastatic
  or Locally Advanced Triple-negative Breast Cancer\nEstimated primary comp
 letion: October 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07151586
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151586-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07151586)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Testi
 ng Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) 
 Combinations Prescribed in an Alterning Pattern to Patients With Metastati
 c or Locally Advanced Triple-negative Breast Cancer\nEstimated primary com
 pletion: October 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07151586
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296746-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05296746)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant and A
 djuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Ca
 ncer\nEstimated primary completion: 1 October 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05296746
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT04557449)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Study to Test the Safety and Tolerability of PF-07220060 in 
 Participants With Advance Solid Tumors\nEstimated primary completion: 7 Oc
 tober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen
 -soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04557449
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04557449)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study to Test the Safety and Tolerability of PF-07220060 i
 n Participants With Advance Solid Tumors\nEstimated primary completion: 7 
 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvest
 rant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04557449
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Letrozole: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study to Test the Safety and Tolerability of PF-07220060 in Participant
 s With Advance Solid Tumors\nEstimated primary completion: 7 October 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9126@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Giredestrant: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Giredestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Test the Safety and Tolerability of PF-07220060 in Particip
 ants With Advance Solid Tumors\nEstimated primary completion: 7 October 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9131@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Test the Safety and Tolerability of PF-07220060 in Particip
 ants With Advance Solid Tumors\nEstimated primary completion: 7 October 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786428-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07786428)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Tailored Neoad
 juvant Chemoimmunotherapy for Stage I TNBC\nEstimated primary completion: 
 31 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07786428
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937605-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Everolimus: Phase 2 readout est. (NCT07937605)
DESCRIPTION:Everolimus\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: KC1086 in Combination With Fulvestrant for HR-Positive\, HER2-Negative
  Advanced Breast Cancer\nEstimated primary completion: November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07937605
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937605-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07937605)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: KC1086 in Combination With Fulvestrant for HR-Positive\, H
 ER2-Negative Advanced Breast Cancer\nEstimated primary completion: Novembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07937
 605
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937605-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Exemestane: Phase 2 readout est. (NCT07937605)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: KC1086 in Combination With Fulvestrant for HR-Positive\, HER2-Negative
  Advanced Breast Cancer\nEstimated primary completion: November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/exemestane#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07937605
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976021-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976021)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Immune PET a
 nd Proteomics for the Assessment of Response to Spatially Fractionated or 
 Palliative Radiotherapy With or Without Immunotherapy\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06976021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518173-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07518173)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A S
 tudy of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzuma
 b and Pertuzumab in Patients With First-line HER2-positive Recurrent or Me
 tastatic Breast Cancer\nEstimated primary completion: December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07518173
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518173-2282@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07518173)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, HER2-Positive Breast Cancer
 .\nStudy: A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Pl
 us Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Re
 current or Metastatic Breast Cancer\nEstimated primary completion: Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-b
 rengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07518173
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222215-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07222215)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in 
 ER+ Breast Cancer (CAPELA)\nEstimated primary completion: 1 December 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07222215
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222215-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07222215)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in
  ER+ Breast Cancer (CAPELA)\nEstimated primary completion: 1 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222215
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2090@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Saruparib: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Saruparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Compa
 red With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in H
 R-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\, 
 BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 18
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarup
 arib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06380751
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Th
 erapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Cami
 zestrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplifie
 d)\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary c
 ompletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Comp
 ared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in 
 HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\,
  BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 1
 8 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06380751
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Th
 erapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Cami
 zestrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplifie
 d)\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary c
 ompletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/camizestrant#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Anastrozole: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Com
 pared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in
  HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\
 , BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 
 18 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ana
 strozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06380751
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Th
 erapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Cami
 zestrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplifie
 d)\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary c
 ompletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine The
 rapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camiz
 estrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified
 )\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary co
 mpletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Letrozole: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Compa
 red With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in H
 R-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\, 
 BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 18
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letro
 zole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06380751
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Exemestane: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Comp
 ared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in 
 HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\,
  BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 1
 8 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exem
 estane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06380751
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05226871)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study for Participants Continuing From Pfizer-sponsored Pa
 lbociclib (a Study Medicine) Studies\nEstimated primary completion: 31 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5226871
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05226871)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study for Participants Continuing From Pfizer-sponsored Pal
 bociclib (a Study Medicine) Studies\nEstimated primary completion: 31 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbocicli
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 226871
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Letrozole: Phase 2 readout est. (NCT05226871)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study for Participants Continuing From Pfizer-sponsored Palbociclib (a 
 Study Medicine) Studies\nEstimated primary completion: 31 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05226871
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565324-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07565324)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Pha
 se II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy fo
 r Patients With HER2-positive Early Breast Cancer (UC HER Trial)\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07565324
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772245-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07772245)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trial of Retifanl
 imab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast C
 ancer\nEstimated primary completion: 31 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07772245
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Study of Patri
 tumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Partic
 ipants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low 
 Positive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\n
 Estimated primary completion: 31 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Study 
 of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents i
 n Participants With High-Risk Early-Stage Triple-Negative or Hormone Recep
 tor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Brea
 st-03)\nEstimated primary completion: 31 December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Study of Patritumab
  Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participant
 s With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Posit
 ive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\nEstim
 ated primary completion: 31 December 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Study of Patritum
 ab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participa
 nts With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Pos
 itive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\nEst
 imated primary completion: 31 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400523-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300210
DTEND;VALUE=DATE:20300211
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07400523)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Ribociclib in Hor
 mone Receptor-positive\, HER2-negative Early Breast Cancer With Residual D
 isease After Neoadjuvant Chemotherapy\nEstimated primary completion: 10 Fe
 bruary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribocicl
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7400523
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Genomi
 cs Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast 
 Cancer (COGNITION-GUIDE)\nEstimated primary completion: March 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Olaparib: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Genomics Guided Tar
 geted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNI
 TION-GUIDE)\nEstimated primary completion: March 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Genomics Guided T
 argeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COG
 NITION-GUIDE)\nEstimated primary completion: March 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT05332561)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: Genomic
 s Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast C
 ancer (COGNITION-GUIDE)\nEstimated primary completion: March 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05645536)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Safety Extension Study for Subjects With HR+\, HER2- Breast 
 Cancer for Subjects Who Have Completed the OVELIA Study\nEstimated primary
  completion: March 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05645536
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05645536)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Safety Extension Study for Subjects With HR+\, HER2- Breast Cancer fo
 r Subjects Who Have Completed the OVELIA Study\nEstimated primary completi
 on: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anast
 rozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05645536
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Letrozole: Phase 3 readout est. (NCT05645536)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Safety Extension Study for Subjects With HR+\, HER2- Breast Cancer for 
 Subjects Who Have Completed the OVELIA Study\nEstimated primary completion
 : March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozo
 le#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5645536
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Exemestane: Phase 3 readout est. (NCT05645536)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Safety Extension Study for Subjects With HR+\, HER2- Breast Cancer for
  Subjects Who Have Completed the OVELIA Study\nEstimated primary completio
 n: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemes
 tane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05645536
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281833-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Capivasertib: Phase 3 readout est. (NCT07281833)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase III Study to Evaluate the Safety\, Efficacy\, and Impact on Qu
 ality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatme
 nt in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Pr
 ior Endocrine-based Treatment\nEstimated primary completion: March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07281833
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459673-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07459673)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-
 HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission\nEstimate
 d primary completion: 4 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07459673
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459673-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07459673)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: HER
 izon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapi
 es and CNS Prophylaxis to Induce Long-Term Remission\nEstimated primary co
 mpletion: 4 March 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07459673
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952557-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05952557)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: An Ad
 juvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2
 - Early Breast Cancer (CAMBRIA-2)\nEstimated primary completion: 4 March 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05952557
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952557-2423@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05952557)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: An Ad
 juvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2
 - Early Breast Cancer (CAMBRIA-2)\nEstimated primary completion: 4 March 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camizestrant#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595255
 7
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: The SAPPHO St
 udy: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic B
 reast Cancer\nEstimated primary completion: 30 March 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: The SAPPHO Study: Sequential Therapy With Curative Intent in de N
 ovo HER2+ Metastatic Breast Cancer\nEstimated primary completion: 30 March
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06439693
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: The
  SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Me
 tastatic Breast Cancer\nEstimated primary completion: 30 March 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: The SAPPHO Study: Sequential Therapy With Curative Intent in de No
 vo HER2+ Metastatic Breast Cancer\nEstimated primary completion: 30 March 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emt
 ansine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06439693
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: The 
 SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Met
 astatic Breast Cancer\nEstimated primary completion: 30 March 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628504-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07628504)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: Sac-
 TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk T
 riple-Negative Breast Cancer Without BRCA Mutations\nEstimated primary com
 pletion: 30 March 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07628504
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126640-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06126640)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Phas
 e III\, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine 
 (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual 
 Invasive Disease Following Neoadjuvant Therapy\nEstimated primary completi
 on: April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06126640
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910398-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT05910398)
DESCRIPTION:Pyrotinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Cont
 inuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-p
 ositive Breast Cancer\nEstimated primary completion: April 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05910398
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191717-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07191717)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Imlun
 estrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Br
 east Cancer in Patients With Minimal Residual Disease\, MIRI Trial\nEstima
 ted primary completion: 30 April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07191717
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520760-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07520760)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Multicenter\, Single-Arm\, Phase II Exploratory Study of Erib
 ulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic 
 Breast Cancer Previously Treated With Antibody-Drug Conjugates\nEstimated 
 primary completion: 30 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07520760
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191717-9192@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07191717)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: Imlu
 nestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive B
 reast Cancer in Patients With Minimal Residual Disease\, MIRI Trial\nEstim
 ated primary completion: 30 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/imlunestrant#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07191717
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841354-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06841354)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: A Study of Sac
 ituzumab Tirumotecan (Sac-TMT\, MK-2870) as Monotherapy and in Combination
  With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast 
 Cancer (MK-2870-011/TroFuse-011)\nEstimated primary completion: 18 May 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06841354
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841354-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06841354)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) as Monotherapy and in C
 ombination With Pembrolizumab (MK-3475) in Participants With Triple-Negati
 ve Breast Cancer (MK-2870-011/TroFuse-011)\nEstimated primary completion: 
 18 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06841354
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701334-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300529
DTEND;VALUE=DATE:20300530
SUMMARY:Ribociclib: Phase 3 readout est. (NCT03701334)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: A Trial to Evalua
 te Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Tr
 eatment in Patients With HR+/HER2- Early Breast Cancer\nEstimated primary 
 completion: 29 May 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03701334
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704829-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05704829)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: NeoAd
 juvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab
 +Pertuzumab in HER2+ Early Breast Cancer\nEstimated primary completion: Ju
 ne 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-
 deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05704829
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544056-9086@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:BEBT-209: Phase 2/3 readout est. (NCT07544056)
DESCRIPTION:BEBT-209\, phase 2/3\, Breast Cancer.\nStudy: A Study of BEBT-2
 09 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Tripl
 e-Negative Breast Cancer\nEstimated primary completion: June 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bebt-209#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07544056
URL:https://assetmemo.bio/drug/bebt-209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203729-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300615
DTEND;VALUE=DATE:20300616
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07203729)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811
 ) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral
  Crisis\nEstimated primary completion: 15 June 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07203729
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monother
 apy and in Combination With Other Antineoplastic Agents in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: July 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in C
 ombination With Other Antineoplastic Agents in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: July 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Tamoxifen (Soltamox): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 1/2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monotherap
 y and in Combination With Other Antineoplastic Agents in Participants With
  Advanced Solid Tumors\nEstimated primary completion: July 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Anastrozole: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Anastrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in 
 Combination With Other Antineoplastic Agents in Participants With Advanced
  Solid Tumors\nEstimated primary completion: July 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monother
 apy and in Combination With Other Antineoplastic Agents in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: July 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monothera
 py and in Combination With Other Antineoplastic Agents in Participants Wit
 h Advanced Solid Tumors\nEstimated primary completion: July 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Co
 mbination With Other Antineoplastic Agents in Participants With Advanced S
 olid Tumors\nEstimated primary completion: July 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Exemestane: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Exemestane\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in C
 ombination With Other Antineoplastic Agents in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: July 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9063@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Tersolisib: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Tersolisib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in C
 ombination With Other Antineoplastic Agents in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: July 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tersolisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9192@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Inluriyo (Imlunestrant): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monothe
 rapy and in Combination With Other Antineoplastic Agents in Participants W
 ith Advanced Solid Tumors\nEstimated primary completion: July 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Olaparib: Phase 2 readout est. (NCT05564377)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Targeted Therapy Directed by Genetic Testing in Treating Patients With L
 ocally Advanced or Advanced Solid Tumors\, The ComboMATCH Screening Trial\
 nEstimated primary completion: 1 July 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05564377)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating Patie
 nts With Locally Advanced or Advanced Solid Tumors\, The ComboMATCH Screen
 ing Trial\nEstimated primary completion: 1 July 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05564377)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating P
 atients With Locally Advanced or Advanced Solid Tumors\, The ComboMATCH Sc
 reening Trial\nEstimated primary completion: 1 July 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05564377)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating Pa
 tients With Locally Advanced or Advanced Solid Tumors\, The ComboMATCH Scr
 eening Trial\nEstimated primary completion: 1 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07683754)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd Based Therapy Followed by Endocrine Therapy Plus Dua
 l HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retr
 eatment With T-DXd\nEstimated primary completion: 4 July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07683754)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: T-DXd Based Thera
 py Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER
 2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd\nEstimated pri
 mary completion: 4 July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT07683754)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual
  HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retre
 atment With T-DXd\nEstimated primary completion: 4 July 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02491697-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02491697)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Immunotherapy Combined With Capecitabine Versus Capecitabine Monothe
 rapy in Advanced Breast Cancer\nEstimated primary completion: August 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02491697
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07716046)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Ful
 vestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Ad
 vanced Breast Cancer\nEstimated primary completion: 31 August 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07716046
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Anastrozole: Phase 2 readout est. (NCT07716046)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/
 HER2+ Advanced Breast Cancer\nEstimated primary completion: 31 August 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07716046
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07716046)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestaciclib Combined With Anti-HER2 and Endocrine Thera
 py for HR+/HER2+ Advanced Breast Cancer\nEstimated primary completion: 31 
 August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07716046
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Letrozole: Phase 2 readout est. (NCT07716046)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HE
 R2+ Advanced Breast Cancer\nEstimated primary completion: 31 August 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07716046
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762703-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07762703)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Breast Cancer.\nStudy: Combination 
 Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic\, 
 PD-L1 Negative (CPS<10)\, gBRCA Negative\, Triple Negative Breast Cancer I
 ncluding BreakVax ImmunoTreatment (Designed and Manufactured Per Patient)\
 , Chemotherapy and Anti PD-1 Therapy\nEstimated primary completion: Septem
 ber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7762703
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive\
 , HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEstim
 ated primary completion: September 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-8458@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Goserelin: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Goserelin\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive\,
  HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/goserelin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-8888@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive
 \, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEsti
 mated primary completion: September 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Letrozole: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive\,
  HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811232-7635@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT07811232)
DESCRIPTION:Eribulin mesylate\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: A Study of AL58805 in Advanced\, Metastatic GYN\, STS or Brea
 st Cancers\nEstimated primary completion: 1 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07811232
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811232-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07811232)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of AL58805 in Advanced\, Metastatic GYN\, STS or
  Breast Cancers\nEstimated primary completion: 1 September 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07811232
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05522491-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Olaparib: Phase 2 readout est. (NCT05522491)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Olaparib in the Tre
 atment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Me
 tastatic Triple-negative Breast Cancer\nEstimated primary completion: 1 Se
 ptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 522491
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment
  Combinations in Patients With Metastatic or Locally Advanced Breast Cance
 r\nEstimated primary completion: 30 September 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tr
 eatment Combinations in Patients With Metastatic or Locally Advanced Breas
 t Cancer\nEstimated primary completion: 30 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Patients With Metastatic or Locally Advanced Brea
 st Cancer\nEstimated primary completion: 30 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Patients With Metastatic or Locally Advanced Brea
 st Cancer\nEstimated primary completion: 30 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Com
 binations in Patients With Metastatic or Locally Advanced Breast Cancer\nE
 stimated primary completion: 30 September 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Itovebi (Inavolisib): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1/2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tre
 atment Combinations in Patients With Metastatic or Locally Advanced Breast
  Cancer\nEstimated primary completion: 30 September 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Patients With Metastatic or Locally Advanced Brea
 st Cancer\nEstimated primary completion: 30 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9034@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tr
 eatment Combinations in Patients With Metastatic or Locally Advanced Breas
 t Cancer\nEstimated primary completion: 30 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Comb
 inations in Patients With Metastatic or Locally Advanced Breast Cancer\nEs
 timated primary completion: 30 September 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9126@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Giredestrant: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Giredestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Patients With Metastatic or Locally Advanced Breast Cancer\
 nEstimated primary completion: 30 September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/giredestrant#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9131@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Atirmociclib: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Atirmociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Patients With Metastatic or Locally Advanced Breast Cancer\
 nEstimated primary completion: 30 September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05933395)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Genetically-informed Therapy for ER+ Breast Cancer Post-CD
 K4/6 Inhibitor\nEstimated primary completion: October 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Neratinib: Phase 2 readout est. (NCT05933395)
DESCRIPTION:Neratinib\, phase 2\, Breast Cancer.\nStudy: Genetically-inform
 ed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\nEstimated primary 
 completion: October 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/neratinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05933395
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05933395)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6
  Inhibitor\nEstimated primary completion: October 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Everolimus: Phase 2 readout est. (NCT05933395)
DESCRIPTION:Everolimus\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibit
 or\nEstimated primary completion: October 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05933395)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Genetically-informed Therapy for ER+ Breast Cancer Post-CD
 K4/6 Inhibitor\nEstimated primary completion: October 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04584853-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04584853)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: PreOperative Endocrine Therapy for Individualised Care Wit
 h Abemaciclib\nEstimated primary completion: October 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04584853
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423611-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07423611)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Ther
 apy in HR-Positive/HER2-Negative Breast Cancer\nEstimated primary completi
 on: 1 October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ibociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07423611
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525766-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06525766)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Po
 sitive\, HER2 Negative Breast Cancer\nEstimated primary completion: 15 Oct
 ober 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6525766
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172478-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301119
DTEND;VALUE=DATE:20301120
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06172478)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 19 November 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06172478
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619365-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07619365)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultr
 alow Advanced or Metastatic Breast Cancer\nEstimated primary completion: 3
 0 November 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tras
 tuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07619365
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963905-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06963905)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: Saci
  Nivo Rela for TNBC\nEstimated primary completion: December 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06963905
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: I-SPY TRIAL: N
 eoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\n
 Estimated primary completion: December 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: I-SPY
  TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast
  Cancer\nEstimated primary completion: December 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Olaparib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: I-SPY TRIAL: Neoadj
 uvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\nEstim
 ated primary completion: December 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT01042379)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: I-SPY
  TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast
  Cancer\nEstimated primary completion: December 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2201@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-
 SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Bre
 ast Cancer\nEstimated primary completion: December 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-S
 PY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Brea
 st Cancer\nEstimated primary completion: December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2243@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Talazoparib\, phase 2\, Breast Cancer.\nStudy: I-SPY TRIAL: Neo
 adjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\nEs
 timated primary completion: December 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to
  Treat Breast Cancer\nEstimated primary completion: December 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Neratinib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Neratinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-SP
 Y TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breas
 t Cancer\nEstimated primary completion: December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/neratinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-SP
 Y TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breas
 t Cancer\nEstimated primary completion: December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-9103@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Veppanu (Vepdegestrant): Phase 2 readout est. (NCT01042379)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 2\, Breast Cancer.\nStudy: I-SP
 Y TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breas
 t Cancer\nEstimated primary completion: December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vepdegestrant#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679360-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07679360)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Stud
 y of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investig
 ator's Choice of Therapy in Subjects With Residual Triple Negative Breast 
 Cancer\nEstimated primary completion: December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07679360
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271992-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301214
DTEND;VALUE=DATE:20301215
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07271992)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: TREND-
 02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab
  Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
 \nEstimated primary completion: 14 December 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07271992
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393374-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06393374)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Sacituzumab Ti
 rumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achi
 eve pCR (MK-2870-012)\nEstimated primary completion: 16 December 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06393374
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393374-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06393374)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: Saci
 tuzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Di
 d Not Achieve pCR (MK-2870-012)\nEstimated primary completion: 16 December
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-ti
 rumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06393374
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828054-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301220
DTEND;VALUE=DATE:20301221
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07828054)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Premedication With Dexamethasone for Preventing Interstiti
 al Lung Disease in Patients With Breast Cancer Treated With Trastuzumab De
 ruxtecan\nEstimated primary completion: 20 December 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07828054
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: PRE-ISPY Phase I/II Oncology Platform Program\nEstimated
  primary completion: 30 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05868226
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2201@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Zanidatamab: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Zanidatamab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: 
 PRE-ISPY Phase I/II Oncology Platform Program\nEstimated primary completio
 n: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05868226
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Tucatinib\, phase 1/2\, Colorectal Cancer.\nStudy: PRE-ISPY Pha
 se I/II Oncology Platform Program\nEstimated primary completion: 30 Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058682
 26
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-3357@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Evorpacept: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Evorpacept\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: P
 RE-ISPY Phase I/II Oncology Platform Program\nEstimated primary completion
 : 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 vorpacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05868226
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179939-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07179939)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Main
 tenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metasta
 tic Breast Cancer: A Phase II Study\nEstimated primary completion: 30 Dece
 mber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0717
 9939
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179939-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07179939)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Maintenance Therapy in HER2-Positive Unresectable Locally Recurren
 t or Metastatic Breast Cancer: A Phase II Study\nEstimated primary complet
 ion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07179939
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981014-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05981014)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Breast Cancer.\nStudy: Study of Au
 tologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Ther
 apy for HER2-Negative Breast Cancer\nEstimated primary completion: 31 Dece
 mber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05981014
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981014-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Epirubicin: Phase 1/2 readout est. (NCT05981014)
DESCRIPTION:Epirubicin\, phase 1/2\, Breast Cancer.\nStudy: Study of Autolo
 gous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy 
 for HER2-Negative Breast Cancer\nEstimated primary completion: 31 December
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0598101
 4
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892274-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07892274)
DESCRIPTION:Pyrotinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Tras
 tuzumab Rezetecan Followed by Pyrotinib\, Fulvestrant\, and Dalpiciclib in
  HR-Positive\, HER2-Positive Advanced Breast Cancer\nEstimated primary com
 pletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07892274
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892274-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07892274)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Rezetecan Followed by Pyrotinib\, Fulvestrant\
 , and Dalpiciclib in HR-Positive\, HER2-Positive Advanced Breast Cancer\nE
 stimated primary completion: 31 December 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07892274
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892274-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07892274)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Trastuzumab Rezetecan Followed by Pyrotinib\, Fulvestrant\, and Dalpi
 ciclib in HR-Positive\, HER2-Positive Advanced Breast Cancer\nEstimated pr
 imary completion: 31 December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07892274
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701941-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07701941)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Patritumab Deruxtecan (HER3-DXd) in Combinatio
 n With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive\, H
 ER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer\nEstimat
 ed primary completion: 1 January 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07701941
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03725059-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310124
DTEND;VALUE=DATE:20310125
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03725059)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Pembr
 olizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemothe
 rapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen
  Receptor-Positive\, Human Epidermal Growth Factor Receptor 2-Negative (ER
 +/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)\nEstimated primary comple
 tion: 24 January 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03725059
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: A Study to Evaluate the Safety\, Tolerability\, Drug Levels\, and
  Preliminary Efficacy of BMS-986507 Combinations in Adult Participants Wit
 h Advanced Solid Tumors\nEstimated primary completion: 26 February 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-2044@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Izalontamab brengitecan: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Izalontamab brengitecan\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: A Study to Evaluate the Safety\, Tolerability\, Drug Le
 vels\, and Preliminary Efficacy of BMS-986507 Combinations in Adult Partic
 ipants With Advanced Solid Tumors\nEstimated primary completion: 26 Februa
 ry 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-
 brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06618287
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432178-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07432178)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small 
 Size High-risk ER-positive Breast Cancer（Cinnamon）\nEstimated primary 
 completion: 31 March 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07432178
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04852887-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310408
DTEND;VALUE=DATE:20310409
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT04852887)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: De-Esca
 lation of Breast Radiation Trial for Hormone Sensitive\, HER-2 Negative\, 
 Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)\n
 Estimated primary completion: 8 April 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04852887
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04852887-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310408
DTEND;VALUE=DATE:20310409
SUMMARY:Exemestane: Phase 3 readout est. (NCT04852887)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: De-Escalation of 
 Breast Radiation Trial for Hormone Sensitive\, HER-2 Negative\, Oncotype R
 ecurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)\nEstimated 
 primary completion: 8 April 2031. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04852887
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288359-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of GVV858 as a Single Agent or in Combination With
  Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Adva
 nced Solid Tumors\nEstimated primary completion: 9 May 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288359-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of GVV858 as a Single Agent or in Combination With Endocrine Th
 erapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tu
 mors\nEstimated primary completion: 9 May 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288359-9062@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:GVV858: Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:GVV858\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Study of GVV858 as a Single Agent or in Combination With Endocrine Thera
 py in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumor
 s\nEstimated primary completion: 9 May 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gvv858#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/gvv858#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630103-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07630103)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab
  Deruxtecan in Advanced Breast Cancer\nEstimated primary completion: June 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07630103
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340541-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07340541)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Evolu
 tionary Clinical Trial for Novel Biomarker-Driven Therapies\nEstimated pri
 mary completion: 2 June 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07340541
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340541-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Everolimus: Phase 2 readout est. (NCT07340541)
DESCRIPTION:Everolimus\, phase 2\, Breast Cancer.\nStudy: Evolutionary Clin
 ical Trial for Novel Biomarker-Driven Therapies\nEstimated primary complet
 ion: 2 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eve
 rolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07340541
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134375-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310626
DTEND;VALUE=DATE:20310627
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06134375)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Breast Cancer.\nStudy: A Study of T
 etrathiomolybdate (TM) Plus Capecitabine\nEstimated primary completion: 26
  June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06134375
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849947-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06849947)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recur
 red After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in
  HR+\, HER2- Metastatic Breast Cancer\nEstimated primary completion: 30 Ju
 ne 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06849
 947
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849947-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06849947)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant With Ribociclib Versus Physician's Choice Trea
 tments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 I
 nhibitors in HR+\, HER2- Metastatic Breast Cancer\nEstimated primary compl
 etion: 30 June 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06849947
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04990921-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04990921)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Palliative Radiation Combined with Pembrolizumab in Unrese
 ctable Metastatic Stage IV Breast Cancer\nEstimated primary completion: 1 
 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04990921
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748260-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07748260)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: De-
 escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early B
 reast\nEstimated primary completion: 1 July 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07748260
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05883852-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05883852)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: EC-THP Versus TCb
 HP in HER2-positive Lymph Node Positive Early Breast Cancer\nEstimated pri
 mary completion: 1 July 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05883852
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894328-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Letrozole: Phase 3 readout est. (NCT07894328)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line The
 rapy in Patients With Advanced or Metastatic Breast Cancer\nEstimated prim
 ary completion: 30 July 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07894328
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894328-9146@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:SHR-6209: Phase 3 readout est. (NCT07894328)
DESCRIPTION:SHR-6209\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Ther
 apy in Patients With Advanced or Metastatic Breast Cancer\nEstimated prima
 ry completion: 30 July 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/shr-6209#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07894328
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894328-9181@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:HRS-6209: Phase 3 readout est. (NCT07894328)
DESCRIPTION:HRS-6209\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Ther
 apy in Patients With Advanced or Metastatic Breast Cancer\nEstimated prima
 ry completion: 30 July 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hrs-6209#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07894328
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753954-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20310819
DTEND;VALUE=DATE:20310820
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07753954)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Medical Imaging to Re-evaluate Elacestrant Clinical Usage\nEstimated 
 primary completion: 19 August 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07753954
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830889-2282@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT06830889)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, HER2-Positive Breast Cancer
 .\nStudy: A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HE
 R2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant 
 Therapy\nEstimated primary completion: October 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06830889
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069595-1980@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311101
DTEND;VALUE=DATE:20311102
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07069595)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: PREDI
 CT-RD: ctDNA Surveillance in TNBC With Residual Disease\nEstimated primary
  completion: 1 November 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07069595
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101159-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07101159)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Dalpici
 clib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patient
 s\nEstimated primary completion: December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07101159
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101159-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07101159)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: Dalpiciclib as Ad
 juvant Therapy for HR-positive/HER2-negative Early-stage Patients\nEstimat
 ed primary completion: December 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07101159
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935226-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311215
DTEND;VALUE=DATE:20311216
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07935226)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib a
 nd Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC\nEstimate
 d primary completion: 15 December 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07935226
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935226-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311215
DTEND;VALUE=DATE:20311216
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07935226)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Induction Trastuzumab Rezetecan Followed by Maintenance Dal
 piciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC
 \nEstimated primary completion: 15 December 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07935226
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766772-2207@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07766772)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tras
 tuzumab Rezetecan Followed by Pyrotinib\, and Trastuzumab Combined With Ca
 pecitabine as First-line Treatment for Advanced HER2-positive Breast Cance
 r\nEstimated primary completion: 31 December 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07766772
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766772-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07766772)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan Followed by Pyrotinib\, and Trastuzumab Comb
 ined With Capecitabine as First-line Treatment for Advanced HER2-positive 
 Breast Cancer\nEstimated primary completion: 31 December 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07766772
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07581834)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Efficac
 y and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for E
 arly HR +/HER2- Breast Cancer: a Multicenter\, Prospective Clinical Study\
 nEstimated primary completion: 31 December 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07581834
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07581834)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: Efficacy and Safe
 ty of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/
 HER2- Breast Cancer: a Multicenter\, Prospective Clinical Study\nEstimated
  primary completion: 31 December 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07581834
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467330-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07467330)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitab
 ine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatmen
 t\nEstimated primary completion: 31 December 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07467330
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467330-9053@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07467330)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabi
 ne vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
 \nEstimated primary completion: 31 December 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07467330
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06078384-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320101
DTEND;VALUE=DATE:20320102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06078384)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Pembrolizumab 
 and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in 
 Resected Early-stage TNBC\nEstimated primary completion: 1 January 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06078384
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790693-2545@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT06790693)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study Evaluating the Efficacy and Safety of Inavolisib Plu
 s CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Par
 ticipants With Endocrine-Sensitive PIK3CA-Mutated\, Hormone Receptor-Posit
 ive\, HER2-Negative Advanced Breast Cancer\nEstimated primary completion: 
 31 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inav
 olisib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06790693
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07679269)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Roll-Over Study o
 f Alpelisib (BYL719) for Continued Access and Long-Term Safety.\nEstimated
  primary completion: 23 March 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-3247@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT07679269)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Roll-Over Study of Alpelisib (BYL719) for Continued Access and
  Long-Term Safety.\nEstimated primary completion: 23 March 2032. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07679269)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Roll-Over Study of Alpelisib (BYL719) for Continued Access
  and Long-Term Safety.\nEstimated primary completion: 23 March 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-9035@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Letrozole: Phase 2 readout est. (NCT07679269)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Ter
 m Safety.\nEstimated primary completion: 23 March 2032. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486687-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07486687)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Pembrolizumab 
 Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With R
 esidual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy\nEstimat
 ed primary completion: April 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07486687
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981001-1963@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05981001)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocyte
 s for Advanced HER2-Negative Breast Cancer\nEstimated primary completion: 
 30 April 2032. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05981001
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729046-2258@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Neratinib: Phase 2 readout est. (NCT07729046)
DESCRIPTION:Neratinib\, phase 2\, Breast Cancer.\nStudy: Neu Direction: Tes
 ting the Efficacy of Adding HER Inhibition to Standard of Care in Metastat
 ic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer\nEstimated primary
  completion: May 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/neratinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07729046
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223698-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320502
DTEND;VALUE=DATE:20320503
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT06223698)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Optimiz
 ing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer\nEs
 timated primary completion: 2 May 2032. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06223698
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223698-9038@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320502
DTEND;VALUE=DATE:20320503
SUMMARY:Exemestane: Phase 3 readout est. (NCT06223698)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Optimizing Extend
 ed Adjuvant Endocrine Therapy in Patients With Breast Cancer\nEstimated pr
 imary completion: 2 May 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06223698
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06374459-9047@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06374459)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Zunsemetinib in Combination With Capecitabine in Patients With Hor
 mone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bon
 e Metastasis\nEstimated primary completion: 31 May 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06374459
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578116-2164@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07578116)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: Adding Surgery and Radiation to the Usual Treatment for HER2-Posi
 tive Breast Cancer That Had Already Spread at Diagnosis\nEstimated primary
  completion: 31 May 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07578116
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578116-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07578116)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Add
 ing Surgery and Radiation to the Usual Treatment for HER2-Positive Breast 
 Cancer That Had Already Spread at Diagnosis\nEstimated primary completion:
  31 May 2032. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07578116
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578116-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Trastuzumab Emtansine: Phase 3 readout est. (NCT07578116)
DESCRIPTION:Trastuzumab Emtansine\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: Adding Surgery and Radiation to the Usual Treatment for HER2-Posit
 ive Breast Cancer That Had Already Spread at Diagnosis\nEstimated primary 
 completion: 31 May 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-emtansine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07578116
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856303-9096@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07856303)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER
 2-Positive Early Breast Cancer After Pathologic Complete Response\nEstimat
 ed primary completion: August 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07856303
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Stud
 y of Patritumab Deruxtecan With Other Anticancer Agents in Participants Wi
 th HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Re
 moved (MK-1022-009)\nEstimated primary completion: 2 August 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: S
 tudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants
  With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically
  Removed (MK-1022-009)\nEstimated primary completion: 2 August 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-2271@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Tucatinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: St
 udy of Patritumab Deruxtecan With Other Anticancer Agents in Participants 
 With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically 
 Removed (MK-1022-009)\nEstimated primary completion: 2 August 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05512364-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Elacestrant: Phase 3 readout est. (NCT05512364)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: Elacestrant for 
 Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
 \nEstimated primary completion: 1 November 2032. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05512364
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06606730-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330101
DTEND;VALUE=DATE:20330102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06606730)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Personalizing 
 the Use of Pembrolizumab for Patients Who Have a Strong Response in Early 
 Triple Negative Breast Cancer\nEstimated primary completion: 1 January 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06606730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407517-9023@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330201
DTEND;VALUE=DATE:20330202
SUMMARY:Everolimus: Phase 3 readout est. (NCT07407517)
DESCRIPTION:Everolimus\, phase 3\, Breast Cancer.\nStudy: Adjuvant Intensif
 ication for LAR\nEstimated primary completion: 1 February 2033. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07407517
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-1991@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A Cl
 inical Study of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With
  Breast Cancer (MK-2870-032)\nEstimated primary completion: 23 March 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumote
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06966700
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-2028@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Olaparib: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Olaparib\, phase 3\, Breast Cancer.\nStudy: A Clinical Study of
  Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With Breast Cancer 
 (MK-2870-032)\nEstimated primary completion: 23 March 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06966700
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Epirubicin: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: A Clinical Study 
 of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With Breast Cance
 r (MK-2870-032)\nEstimated primary completion: 23 March 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06966700
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178730-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07178730)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: NeoAdjuvant Th
 erapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy i
 n Clinical Stage II-III\, Triple-negative Early Breast Cancer\nEstimated p
 rimary completion: 31 March 2033. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07178730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178730-1992@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT07178730)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: NeoAdj
 uvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemot
 herapy in Clinical Stage II-III\, Triple-negative Early Breast Cancer\nEst
 imated primary completion: 31 March 2033. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07178730
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929768-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05929768)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Shorter Chemo-
 Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative 
 Breast Cancer\nEstimated primary completion: 31 March 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05929768
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060807-1981@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330714
DTEND;VALUE=DATE:20330715
SUMMARY:Patritumab Deruxtecan: Phase 3 readout est. (NCT07060807)
DESCRIPTION:Patritumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Clinical Study of Patritumab Deruxtecan to Treat Breast C
 ancer (MK-1022-016)\nEstimated primary completion: 14 July 2033. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07060807
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242352-9037@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Elacestrant: Phase 3 readout est. (NCT07242352)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: Marker - Adjuste
 d Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment
  in Genomically and/or Clinically High-risk ER+/HER2- eBC\nEstimated prima
 ry completion: 30 September 2033. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07242352
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07237256-2228@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07237256)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Chemotherapy De-e
 scalation in HR +\, HER2-\, Intermediate-risk Early Breast Cancer Treated 
 With Adjuvant Ribociclib\nEstimated primary completion: 30 November 2033. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07237256
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015853-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07015853)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: ASTRAEA: Reinv
 igorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination My
 eloid Inhibition and Radiation\nEstimated primary completion: December 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07015853
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190443-2159@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20340206
DTEND;VALUE=DATE:20340207
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT07190443)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Adjuv
 ant Abemaciclib for Locoregional Recurrence of HR-positive\, HER2-negative
  Breast Cancer (JCOG2313\, AURA)\nEstimated primary completion: 6 February
  2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071904
 43
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-2241@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06348134)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Ass
 essing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With
  HER2+ Breast Cancer Before and After Surgery\nEstimated primary completio
 n: 1 July 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06348134
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-2244@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT06348134)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian
  Women With HER2+ Breast Cancer Before and After Surgery\nEstimated primar
 y completion: 1 July 2034. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-emtansine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06348134
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06348134)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Assessi
 ng the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER
 2+ Breast Cancer Before and After Surgery\nEstimated primary completion: 1
  July 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen
 -soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06348134
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441460-2506@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20340807
DTEND;VALUE=DATE:20340808
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT07441460)
DESCRIPTION:Docetaxel (HB1801)\, phase 3\, HER2-Positive Breast Cancer.\nSt
 udy: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant The
 rapy for Resectable HER2-Positive Breast Cancer\nEstimated primary complet
 ion: 7 August 2034. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ocetaxel-hb1801#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07441460
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441460-9113@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20340807
DTEND;VALUE=DATE:20340808
SUMMARY:Epirubicin: Phase 3 readout est. (NCT07441460)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: A Phase III Study
  of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HE
 R2-Positive Breast Cancer\nEstimated primary completion: 7 August 2034. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07441460
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802626-7646@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20341030
DTEND;VALUE=DATE:20341031
SUMMARY:Capivasertib: Phase 3 readout est. (NCT07802626)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Adding Capivasertib to Standard Treatment in HR Positive\, HER2 Nega
 tive Metastatic Breast Cancer Based on ctDNA Testing\nEstimated primary co
 mpletion: 30 October 2034. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/capivasertib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07802626
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802626-9030@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20341030
DTEND;VALUE=DATE:20341031
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07802626)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Adding Capivasertib to Standard Treatment in HR Positive\,
  HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing\nEstimated 
 primary completion: 30 October 2034. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07802626
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552181-1973@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20350930
DTEND;VALUE=DATE:20351001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07552181)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Phase II Trial
  of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in P
 atients With Early Stage Triple Negative Breast Cancer\nEstimated primary 
 completion: September 2035. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07552181
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502820-8457@assetmemo.bio
DTSTAMP:20261121T004955Z
DTSTART;VALUE=DATE:20360831
DTEND;VALUE=DATE:20360901
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT07502820)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: The POW
 ER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy i
 n Breast cancER\nEstimated primary completion: August 2036. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07502820
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
